Human cd33 antibodies and uses thereof

By developing nanobodies or antigen-binding fragments that specifically bind to CD33, the unknown function of CD33 in the treatment of leukemia has been resolved, enabling highly efficient targeted therapy of CD33 and providing a potential means of treating leukemia.

CN116867806BActive Publication Date: 2026-11-10SIMCERE ZAIMING PHARMACEUTICAL CO LTD
View PDF 21 Cites 0 Cited by

Patent Information

Application Number
CN202280013967.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-02-10
Filing Date
2022-02-09
Publication Date
2026-11-10
Estimated Expiration
2042-02-09

AI Technical Summary

Technical Problem

The functional role of CD33 in the treatment of leukemia is unknown in the current technology, and there is a lack of effective targeted therapies.

Method used

Nanobodies or antigen-binding fragments that specifically bind to CD33, containing specific combinations of CDR1, CDR2, and CDR3 sequences, have been developed to bind to CD33 with high affinity and can be used to prepare pharmaceutical compositions for the treatment of tumors.

Benefits of technology

It achieves highly efficient targeting of CD33, providing a potential treatment for leukemia, especially tumors such as myelodysplastic syndrome, acute myeloid leukemia, and chronic myeloid leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116867806B_ABST
    Figure CN116867806B_ABST
Patent Text Reader

Abstract

An antibody against CD33, its preparation method and application. The antibody against CD33 has high affinity to CD33 protein, and can be used in the preparation of drugs for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese Patent Application No. 202110182902.1, filed on February 10, 2021, entitled "Human CD33 Antibody and Its Use", the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention belongs to the fields of bioengineering and biomedicine; it relates to human CD33 antibody, the nucleic acid encoding it, antibody preparation method, pharmaceutical composition containing the antibody, and the use of the pharmaceutical composition in the treatment of tumors. Background Technology

[0003] In the early 1980s, Andrews et al. identified CD33 as a marker for myeloid leukemia (Blood 62, 24-132, 1983). CD33 is a cell surface antigen specifically expressed on myeloid cells, including myeloid leukemia cells. It is the smallest member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. CD33 has a molecular weight of 67 kDa and is a type I transmembrane receptor protein composed of 364 amino acids. Its N-terminus is located extracellularly, with the terminal amino acids forming a conserved V-set immunoglobulin-like domain and a variable C2-set domain. The V-set specifically recognizes and binds to sialic acid. The cytoplasmic tail contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like structure, which transmits inhibitory signals intracellularly by binding to tyrosine phosphatase, thereby regulating cell growth. The ITIM sequence in the CD33 molecule differs from other Siglec molecules, as the hydrophobic amino acid preceding tyrosine is replaced by leucine and threonine. Primary structure analysis reveals that the CD33 molecule is highly conserved across various organisms.

[0004] CD33 is expressed in early multilineage hematopoietic progenitor cells and bone marrow monocyte precursors. It is not expressed in pluripotent hematopoietic stem cells (Andrews et al., Journal of Experimental Medicine 169, 1721-1731, 1989). Its expression is upregulated in mature granulocytes but retained in macrophages, monocytes, and dendritic cells (Andrews et al., Blood 62, 24-132, 1983). In addition to bone marrow monocytes, Valent et al. found that CD33 is also expressed in human mast cells and blood basophils (Blood 15, 73(7):1778-85, 1989).

[0005] The extracellular domain of CD33, which binds to sialic acid, participates in cell-cell adhesion. Intracellular immune receptor tyrosine inhibitory motifs (ITIMs) confer inhibitory signals to cells, thereby affecting proliferation and cell survival. The actual signal transduction pathway of CD33 is still poorly understood, but von Gunten et al. suggest it involves the recruitment of ITIMs and ITIM-like motifs and tyrosine phosphatases (Ann. NYAcad. Sci. 1143:61-82, 2008). Brinkman-Vander Linden et al. have defined murine CD33 homologs, but their functional comparability with human CD33 remains questionable (Mol Cell Biol., 23(12):4199-206, 2003). The functional role of human CD33 in normal and malignant leukocytes remains unknown.

[0006] Several publications have described CD33 as a stable cell surface marker expressed in primary AML and CML cells in 70% to 100% of tested patients (Plesa et al., Cancer 112(3), 572-80, 2007; Hauswirt et al., Eur J Clin Invest. Jan 73-82, 2007; Scheinberg et al., Leukemia, Vol. 3, 440-445, 1989). CD33 is expressed in malignant myeloid blasts (which represent the majority of malignant cells in the peripheral blood and bone marrow of leukemia patients) and leukemia stem cells (i.e., a relatively small number of poorly differentiated cells in the bone marrow, characterized by their ability to self-renew and maintain the leukemia lineage hierarchy), while low levels of CD33 are expressed only in a subset of normal hematopoietic stem cells. CD33 can regulate leukocyte function during inflammatory and immune responses, thus CD33 is an ideal target for the treatment of acute myeloid leukemia.

[0007] Nanobodies (Nb) are genetically engineered antibodies containing only a single structural domain. In 1993, Belgian scientist Hamers-Casterman C discovered a natural heavy chain antibody in camel blood that contained only the heavy chain and no light chain (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 363(6428):446–8(1993)). Although heavy chain antibodies lack the light chain compared to ordinary antibodies, they still retain the ability to bind antigens. After cloning the variable region of the heavy chain antibody in camel, a single domain antibody (sdAb) composed of only one heavy chain variable region is obtained, which is called a nanobody or VHH antibody (variable heavy chain domain of a heavy chain antibody). Nanobodies not only have a molecular weight that is only 1 / 10 that of ordinary antibodies, but also possess more flexible chemical properties, better stability, higher solubility, easier expression, higher penetration into tumor tissue, and easier conjugation to other molecules. Therefore, nanobody technology has broad application prospects in the field of therapeutic antibodies. Summary of the Invention

[0008] This invention provides an antibody or antigen-binding fragment capable of binding to human CD33, a nucleic acid, a vector, a cell encoding the antibody or antigen-binding fragment, a method for preparing the antibody or antigen-binding fragment, a pharmaceutical composition containing the antibody or antigen-binding fragment, and related uses of the pharmaceutical composition for treating tumors.

[0009] In a first aspect, the present invention provides an antibody or antigen-binding fragment that specifically binds to CD33, said antibody or antigen-binding fragment comprising: CDR1, CDR2, and CDR3; said CDR1, CDR2, and CDR3 having any sequence combination selected from the following or having a sequence combination having 1, 2, 3, or more amino acid insertions, deletions, and / or substitutions compared to said sequence combination:

[0010] (1) The CDR1 can be selected from SEQ ID NO: 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104, 107, 110, 113, 116, 119, 122, 125, 128, 131, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 170, 173, 176, 179, 182, 185, 188, 226, 227;

[0011] (2) The CDR2 can be selected from SEQ ID NO: 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 229, 230;

[0012] (3) The CDR3 can be selected from SEQ ID NO: 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 172, 175, 178, 181, 184, 187, 190, 228;

[0013] Each CDR1, CDR2, and CDR3 is coded according to the KABAT, Chothia, or IMGT commonality analysis method;

[0014] Preferably, the substitution is a substitution of a conserved amino acid.

[0015] In some embodiments, CDR1, CDR2 and CDR3 respectively comprise CDR1, CDR2 and CDR3 selected from the VHH structural domain shown in any one of SEQ ID NO: 11~28 or 193~223;

[0016] Preferably, according to the KABAT, Chothia, or IMGT numbering system, the antibody or antigen-binding fragment comprises CDR1, CDR2, and CDR3:

[0017] (1) CDR1 is selected from SEQ ID NO: 29, 83, 137, CDR2 is selected from SEQ ID NO: 30, 84, 138, and CDR3 is selected from SEQ ID NO: 31, 85, 139;

[0018] (2) CDR1 is selected from SEQ ID NO: 32, 86, 140, CDR2 is selected from SEQ ID NO: 33, 87, 141, and CDR3 is selected from SEQ ID NO: 34, 88, 142;

[0019] (3) CDR1 is selected from SEQ ID NO: 35, 89, 143, 226, 227, CDR2 is selected from SEQ ID NO: 36, 90, 144, and CDR3 is selected from SEQ ID NO: 37, 91, 145;

[0020] (4) CDR1 is selected from SEQ ID NO: 38, 92, 146, CDR2 is selected from SEQ ID NO: 39, 93, 147, and CDR3 is selected from SEQ ID NO: 40, 94, 148;

[0021] (5) The CDR1 is selected from SEQ ID NO: 41, 95, 149, the CDR2 is selected from SEQ ID NO: 42, 96, 150, 229, and the CDR3 is selected from SEQ ID NO: 43, 97, 151, 228;

[0022] (6) CDR1 is selected from SEQ ID NO: 44, 98, 152, CDR2 is selected from SEQ ID NO: 45, 99, 153, and CDR3 is selected from SEQ ID NO: 46, 100, 154;

[0023] (7) The CDR1 is selected from SEQ ID NO: 47, 101, 155, the CDR2 is selected from SEQ ID NO: 48, 102, 156, and the CDR3 is selected from SEQ ID NO: 49, 103, 157;

[0024] (8) The CDR1 is selected from SEQ ID NO: 50, 104, 158, the CDR2 is selected from SEQ ID NO: 51, 105, 159, and the CDR3 is selected from SEQ ID NO: 52, 106, 160;

[0025] (9) The CDR1 is selected from SEQ ID NO: 53, 107, 161, the CDR2 is selected from SEQ ID NO: 54, 108, 162, 230, and the CDR3 is selected from SEQ ID NO: 55, 109, 163;

[0026] (10) The CDR1 is selected from SEQ ID NO: 56, 110, 164, the CDR2 is selected from SEQ ID NO: 57, 111, 165, and the CDR3 is selected from SEQ ID NO: 58, 112, 166;

[0027] (11) The CDR1 is selected from SEQ ID NO: 59, 113, 167, the CDR2 is selected from SEQ ID NO: 60, 114, 168, and the CDR3 is selected from SEQ ID NO: 61, 115, 169;

[0028] (12) The CDR1 is selected from SEQ ID NO: 62, 116, 170, the CDR2 is selected from SEQ ID NO: 63, 117, 171, and the CDR3 is selected from SEQ ID NO: 64, 118, 172;

[0029] (13) The CDR1 is selected from SEQ ID NO: 65, 119, 173, the CDR2 is selected from SEQ ID NO: 66, 120, 174, and the CDR3 is selected from SEQ ID NO: 67, 121, 175;

[0030] (14) The CDR1 is selected from SEQ ID NO: 68, 122, 176, the CDR2 is selected from SEQ ID NO: 69, 123, 177, and the CDR3 is selected from SEQ ID NO: 70, 124, 178;

[0031] (15) The CDR1 is selected from SEQ ID NO: 71, 125, 179, the CDR2 is selected from SEQ ID NO: 72, 126, 180, and the CDR3 is selected from SEQ ID NO: 73, 127, 181;

[0032] (16) The CDR1 is selected from SEQ ID NO: 74, 128, 182, the CDR2 is selected from SEQ ID NO: 75, 129, 183, and the CDR3 is selected from SEQ ID NO: 76, 130, 184;

[0033] (17) The CDR1 is selected from SEQ ID NO: 77, 131, 185, the CDR2 is selected from SEQ ID NO: 78, 132, 186, and the CDR3 is selected from SEQ ID NO: 79, 133, 187;

[0034] (18) CDR1 is selected from SEQ ID NO: 80, 134, 188; CDR2 is selected from SEQ ID NO: 81, 135, 189; and CDR3 is selected from SEQ ID NO: 82, 136, 190; or,

[0035] (19) A sequence combination having 1, 2, 3 or more amino acid insertions, deletions and / or substitutions compared to the sequence combinations (1) to (18) above; preferably, the substitution is a substitution of a conserved amino acid.

[0036] In some embodiments, preferably, the antibody or antigen-binding fragment comprises a combination of CDR1, CDR2, and CDR3 sequences selected from SEQ ID NO:11-28 or 193-223; or, it comprises a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the aforementioned CDR1, CDR2, and / or CDR3.

[0037] In some embodiments, preferably, the antibody or antigen-binding fragment comprises the FR region of the VHH domain shown in any one of SEQ ID NO: 11-28 or 193-223; optionally, the antibody or antigen-binding fragment comprises a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the FR region of the VHH domain shown in any one of SEQ ID NO: 11-28 or 193-223; or, .... NO: The sequence containing at most 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 mutations compared to the FR region of the VHH domain shown in any one of NO: 11-28 or 193-223; the mutations may be selected from insertions, deletions and / or substitutions, the substitutions being preferably substitutions of conserved amino acids.

[0038] In some embodiments, preferably, the antibody or antigen-binding fragment comprises the sequence shown in any one of SEQ ID NO: 11-28 or 193-223; optionally, the antibody or antigen-binding fragment comprises a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the sequence shown in any one of SEQ ID NO: 11-28 or 193-223; or, ... SEQ ID NO: 11-28 or 193-223. NO: A sequence having undergone a mutation of up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 compared to any of the sequences shown in NO: 11-28 or 193-223; the mutation may be selected from insertion, deletion, and / or substitution, the substitution preferably being a substitution of a conserved amino acid.

[0039] In some embodiments, preferably, the dissociation constant (KD) of the antibody or antigen-binding fragment binding to human CD33 is not greater than 100 nM; and the dissociation constant (KD) of the fragment binding to monkey CD33 is not greater than 100 nM.

[0040] Further, in some embodiments, the antibody or antigen-binding fragment may or may not contain an antibody heavy chain constant region; optionally, the antibody heavy chain constant region may be selected from human, alpaca, mouse, rat, rabbit, or sheep; optionally, the antibody heavy chain constant region may be selected from IgG, IgM, IgA, IgE, or IgD, and the IgG may be selected from IgG1, IgG2, IgG3, or IgG4; optionally, the heavy chain constant region may be selected from the Fc region, CH3 region, heavy chain constant region without CH1 fragment, or complete heavy chain constant region; preferably, the heavy chain constant region is a human Fc region, more preferably having an amino acid sequence as shown in SEQ ID NO: 191; preferably, the antibody or antigen-binding fragment is a heavy chain antibody.

[0041] Furthermore, in some embodiments, the antibody or antigen-binding fragment is: (1) a chimeric antibody or a fragment thereof; (2) a humanized antibody or a fragment thereof; or, (3) a fully human antibody or a fragment thereof.

[0042] Furthermore, in some embodiments, the antibody or antigen-binding fragment is also conjugated with a therapeutic agent or a tracer; preferably, the therapeutic agent is selected from radioactive isotopes, cytotoxic agents, or immunomodulators, and the tracer is selected from radiographic contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents, and photosensitizers; more preferably, the cytotoxic agent is selected from alkaloids, methotrexate, anthracycline antibiotics (doxorubicin), or taxanes.

[0043] Furthermore, in some embodiments, the antibody or antigen-binding fragment is also linked to another functional molecule, which may be selected from one or more of the following: signal peptides, protein tags, or cytokines.

[0044] In a second aspect, the present invention provides a multispecific antibody comprising the antibody or antigen-binding fragment described in the first aspect; preferably, the multispecific antibody further comprises an antibody or antigen-binding fragment that specifically binds to an antigen other than CD33 or binds to a CD33 epitope different from the antibody or antigen-binding fragment described in the first aspect.

[0045] In some embodiments, preferably, the antigen other than CD33 may be selected from: CD3, preferably CD3ε; CD16, preferably CD16A; CS32B; PD-1; PD-2; PD-L1; NKG2D; CD19; CD20; CD40; CD47; 4-1BB; CD137; EGFR; EGFRvIII; TNF-alpha; MSLN; HER2; HER3; HSA; CD5; CD27; EphA2; EpCAM; MUC1; MUC16; CEA; Claudin18.2; folate receptor; Claudin6; WT1; NY-ESO-1; MAGE3; ASGPR1 or CDH16.

[0046] In some embodiments, preferably, the multispecific antibody may be a bispecific antibody, a trispecific antibody, or a tetraspecific antibody, and the multispecific antibody may be bivalent, tetravalent, or hexavalent.

[0047] In a third aspect, the present invention provides a chimeric antigen receptor (CAR) comprising at least an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises an antibody or antigen-binding fragment optionally selected from the first aspect.

[0048] In a fourth aspect, the present invention provides an immune effector cell that expresses the chimeric antigen receptor described in the third aspect, or contains a nucleic acid fragment encoding the chimeric antigen receptor described in the third aspect; preferably, the immune effector cell is selected from T cells, NK cells (natural killer cells), NKT cells (natural killer T cells), DNT cells (double negative T cells), monocytes, macrophages, dendritic cells, or mast cells, wherein the T cells are preferably selected from cytotoxic T cells, regulatory T cells, or helper T cells; preferably, the immune effector cell is an autologous immune effector cell or an allogeneic immune effector cell.

[0049] In a fifth aspect, the present invention provides isolated nucleic acid fragments capable of encoding the antibody or antigen-binding fragment of the first aspect, the multispecific antibody of the second aspect, or the chimeric antigen receptor of the third aspect.

[0050] In a sixth aspect, the present invention provides a vector comprising the isolated nucleic acid fragments described in the fifth aspect.

[0051] In a seventh aspect, the present invention provides a host cell comprising the carrier described in the sixth aspect above; preferably, the cell is a prokaryotic cell or a eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast), insect cells or mammalian cells (CHO cell line or 293T cell line).

[0052] In an eighth aspect, the present invention also provides a method for preparing an antibody or antigen-binding fragment, or a multispecific antibody, the method comprising culturing the cells described in the seventh aspect above, and isolating the antibody or antigen-binding fragment expressed by the cells under suitable conditions, or isolating the multispecific antibody expressed by the cells.

[0053] In a ninth aspect, the present invention also provides a method for preparing immune effector cells, the method comprising introducing a nucleic acid fragment encoding the CAR of the third aspect into the immune effector cells, optionally, the method further comprising initiating the expression of the CAR of the third aspect into the immune effector cells.

[0054] In a tenth aspect, the present invention also provides a pharmaceutical composition comprising, optionally, an antibody or antigen-binding fragment selected from the first aspect, or a multispecific antibody selected from the second aspect, or an immune effector cell selected from the fourth aspect, or a nucleic acid fragment selected from the fifth aspect, or a carrier selected from the sixth aspect; or a product prepared by the methods of the eighth and ninth aspects; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent, or adjuvant; optionally, the pharmaceutical composition further comprises an additional antitumor agent.

[0055] In an eleventh aspect, the present invention also provides a method for preventing and / or treating tumors, comprising administering to a patient in need an effective amount of an antibody or antigen-binding fragment optionally from the first aspect, or a multispecific antibody optionally from the second aspect, or an immune effector cell optionally from the fourth aspect, or a nucleic acid fragment optionally from the fifth aspect, or a carrier optionally from the sixth aspect; or a product prepared by the methods of the eighth and ninth aspects; or a pharmaceutical composition optionally from the tenth aspect. The tumor is preferably myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and promyelocytic leukemia (PML).

[0056] In a twelfth aspect, the present invention provides the use of an antibody or antigen-binding fragment optionally selected from the first aspect, or a multispecific antibody optionally selected from the second aspect, or an immune effector cell optionally selected from the fourth aspect, or a nucleic acid fragment optionally selected from the fifth aspect, or a carrier optionally selected from the sixth aspect; or a product prepared by the methods described in the eighth and ninth aspects; or the use of the pharmaceutical composition described in the tenth aspect in the preparation of a medicament for the prevention and / or treatment of tumors; wherein the tumor is preferably myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and promyelocytic leukemia (PML).

[0057] In a thirteenth aspect, the present invention provides a kit comprising an antibody or antigen-binding fragment optionally selected from the first aspect, or a multispecific antibody optionally selected from the second aspect, or an immune effector cell optionally selected from the fourth aspect, or a nucleic acid fragment optionally selected from the fifth aspect, or a vector optionally selected from the sixth aspect; or a product prepared by the methods described in the eighth and ninth aspects.

[0058] In a fourteenth aspect, the present invention provides a method for inhibiting the proliferation or migration of CD33-expressing cells in vitro, characterized in that the cells are contacted with an antibody or antigen-binding fragment, optionally from the first aspect, under conditions that a complex can be formed between the antibody or antigen-binding fragment and CD33.

[0059] Terms and definitions:

[0060] Unless otherwise stated, the terminology used in this invention has the meaning commonly understood by one of ordinary skill in the art. For terms explicitly defined in this invention, the meaning of the term shall be as defined thereon.

[0061] Furthermore, unless otherwise stated herein, singular terms shall include plural terms, and plural terms shall include singular terms. More specifically, as used in this specification and the appended claims, unless otherwise expressly indicated, the singular forms “a” and “this” include plural indicators.

[0062] The terms “comprising,” “including,” and “having” are used interchangeably in this document to indicate the inclusiveness of a scheme, meaning that the scheme may contain elements other than those listed. It should also be understood that the use of “comprising,” “including,” and “having” in this document also provides for schemes “consisting of…”.

[0063] When used herein, the term “and / or” includes the meaning of “and,” “or,” and “all or any other combination of elements linked by the term.”

[0064] The terms “optional” or “optionally” in this document mean that the event or circumstance described below may, but is not necessarily, occur, including the possibility that the event or circumstance may or may not occur. For example, “optionally containing 1-3 antibody heavy chain variable regions” means that antibody heavy chain variable regions may, but are not required to, be present; if present, they may be 1, 2, or 3.

[0065] The term "CD33" in this article refers to the smallest member of the sialicacid-binding immunoglobulin-like lectin (Siglec) family. It is a type I transmembrane receptor protein with a molecular weight of 67 kDa, composed of 364 amino acids. Its N-terminus is located extracellularly, with the terminal amino acids forming a conserved V-set immunoglobulin-like domain and a variable C2-set domain. The V-set specifically recognizes and binds to sialic acid. The cytoplasmic tail contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like structure, which transmits inhibitory signals intracellularly by binding to tyrosine phosphatase, thereby regulating cell growth. The ITIM sequence in the CD33 molecule differs from other Siglec molecules; the hydrophobic amino acid preceding the tyrosine residue is replaced by leucine and threonine. Primary structure analysis reveals that the CD33 molecule is highly conserved across various organisms. The term "CD33" includes the CD33 protein of any human and non-human animal species, and specifically includes human CD33 as well as CD33 of non-human mammals.

[0066] The term "specific binding" in this article refers to the ability of antigen-binding molecules (such as antibodies) to specifically bind to antigens and substantially the same antigens with high affinity, but not to unrelated antigens with high affinity. Affinity is usually reflected by the equilibrium dissociation constant (KD), where a lower KD indicates higher affinity. For example, high affinity for antibodies typically refers to a KD of approximately 10.-7 M or lower, approximately 10 -8 M or lower, approximately 1×10 -9 M or lower, approximately 1×10 - 10 M or lower, 1×10 -11 M or lower or 1×10 -12 M or lower KD. KD is calculated as follows: KD = Kd / Ka, where Kd represents the dissociation rate and Ka represents the binding rate. The equilibrium dissociation constant KD can be measured using methods known in the art, such as surface plasmon resonance (e.g., Biacore) or equilibrium dialysis.

[0067] The term "antigen-binding molecule" is used in the broadest sense in this document to refer to a molecule that specifically binds to an antigen. Exemplarily, antigen-binding molecules include, but are not limited to, antibodies or antibody mimics. "Antibody mimic" refers to an organic compound or binding domain that can specifically bind to an antigen but is independent of the antibody structure. Exemplarily, antibody mimics include, but are not limited to, affibody, affitin, affilin, designed ankylosing spondylamine repeat (DARPin), aptamers, or Kunitz-type domain peptides.

[0068] The term “antibody” in this article, used in its broadest sense, refers to a polypeptide or combination of polypeptides containing sufficient sequences from the variable regions of the immunoglobulin heavy chain and / or from the variable regions of the immunoglobulin light chain, thereby enabling specific binding to an antigen. The term “antibody” in this article encompasses a wide range of forms and structures, provided they exhibit the desired antigen-binding activity. The term “antibody” in this article includes alternative protein scaffolds or artificial scaffolds with transplanted complementarity-determining regions (CDRs) or CDR derivatives. Such scaffolds include antibody-derived scaffolds (containing mutations introduced to, for example, stabilize the three-dimensional structure of the antibody) and fully synthetic scaffolds containing, for example, biocompatible polymers. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, 53(1):121-129 (2003); Roque et al., Biotechnol. Prog. 20:639-654 (2004). Such scaffolds may also include non-antibody-derived scaffolds, such as scaffold proteins known in the art for use in transplanting CDRs, including but not limited to tendinins, fibronectins, peptide aptamers, etc.

[0069] The term "antibody" in this article includes a typical "quadruple-chain antibody," which belongs to the immunoglobulin family composed of two heavy chains (HC) and two light chains (LC). The heavy chain refers to a polypeptide chain consisting of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain in the N-to-C-terminal direction. Optionally, when the full-length antibody is an IgE isotype, it also includes a heavy chain constant region CH4 domain. The light chain is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) in the N-to-C-terminal direction. Heavy chains are linked to each other and to each other with disulfide bonds, forming a "Y"-shaped structure. Because the amino acid composition and sequence of the immunoglobulin heavy chain constant region differ, their antigenicity also differs. Based on this, the "immunoglobulins" in this article can be divided into five classes, or isotypes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε chains, respectively. Within the same class of Ig, differences in the amino acid composition of the hinge region and the number and position of disulfide bonds in the heavy chain can further lead to different subclasses. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4, and IgA into IgA1 and IgA2. Light chains are classified as κ or λ chains based on differences in their constant regions. Each of the five classes of Ig can possess either a κ or λ chain.

[0070] The term "antibody" in this article also includes antibodies that do not contain light chains, such as heavy-chain antibodies (HCAbs) produced by dromedary camels (Camelus dromedarius), Bactrian camels (Camelus bactrianus), llamas (Lama glama), guanocamels (Lama guanicoe), and alpacas (Vicugna pacos), as well as immunoglobulin new antigen receptors (IgNARs) found in cartilaginous fish such as sharks.

[0071] The term "heavy-chain antibody" in this article refers to a second type of antibody known to exist naturally in camelidae species, which naturally lacks the light chain and the CH1 constant region. Heavy-chain antibodies (HCAbs) consist of two heavy chains linked by covalent disulfide bonds. Each heavy chain in an HCAb has a variable domain at one end. To distinguish them from the variable domains (VH) of "conventional" camelidae antibody heavy chains, the variable domains of HCAbs are referred to as "VHHs." VHH domains are entirely different from VH domains; they are encoded by different gene segments in the camelidae genome.

[0072] The terms "VHH domain," "nanobody," and "single domain antibody" (sdAb) in this article have the same meaning and are used interchangeably. They refer to the cloning of the variable region of a heavy chain antibody to construct a single-domain antibody consisting of only one heavy chain variable region. This is the smallest antigen-binding fragment with complete function. Typically, a naturally occurring heavy chain antibody lacking both the light chain and the heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody consisting of only one heavy chain variable region.

[0073] Further descriptions of "heavy chain antibodies," "single-domain antibodies," "VHH domains," and "nanobodies" can be found in: Hamers-Casterman et al., Nature. 1993; 363; 446-8; Muyldermans' review article (Reviews in Molecular Biotechnology 74: 277-302, 2001); and the following patent applications, which are mentioned as general background art: WO 94 / 04678, WO 95 / 04079, and WO 96 / 34103; WO94 / 25591, WO 99 / 37681, WO 00 / 40968, WO 00 / 43507, WO 00 / 65057, WO 01 / 40310, WO 01 / 44301, EP 1134231, and WO 02 / 48193; WO97 / 49805, WO WO 01 / 21817, WO 03 / 035694, WO 03 / 054016 and WO 03 / 055527; WO 03 / 050531; WO 01 / 90190; WO03 / 025020; and WO 04 / 041867, WO 04 / 041862, WO 04 / 041865, WO04 / 041863, WO 04 / 062551, WO 05 / 044858, WO 06 / 40153, WO 06 / 079372, WO 06 / 122786, WO06 / 122787 and WO 06 / 122825 and other prior art mentioned in these applications.

[0074] The term "antibody" as used herein can be derived from any animal, including but not limited to humans and non-human animals. Non-human animals can be selected from primates, mammals, rodents, and vertebrates, such as camels, llamas, ostriches, alpacas, sheep, rabbits, mice, rats, or cartilaginous fish (e.g., sharks). As used herein, the term "antigen-binding fragment" refers to one or more antibody fragments that retain the ability to specifically bind to a target antigen. The antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Antibody fragments can be Fab, F(ab')2, scFv, SMIP, biantibodies, triantibodies, affibody, nanobody, aptamer, or domain antibody. Examples of binding fragments encompassing the term "antigen-binding fragment" of antibody include, but are not limited to: (i) Fab fragments, a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) F(ab)2 fragments, a bivalent fragment comprising two Fab fragments linked by disulfide bonds in a hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains of an antibody arm; (v) dAbs containing VH and VL domains; (vi) dAb fragments consisting of VH domains (Ward et al., Nature 341:544-546, 1989); (vii) dAbs consisting of either VH or VL domains; (viii) separate complementarity-determining regions (CDRs); (ix) heavy chain antibody fragments consisting of VHH and CH2, CH3; and (x) combinations of two or more separate CDRs, which may optionally be linked by synthetic linkers. Furthermore, although the two domains VL and VH of the Fv fragment are encoded by independent genes, these two domains can be joined using recombination methods via a linker that enables the creation of a single protein chain in which the VL and VH regions pair to form a monovalent molecule (referred to as a single-chain Fv (scFv); see, for example, Bird et al., Science 242:423-426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments are screened for use in the same manner as intact antibodies. Antigen-binding fragments can be generated by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or, in some embodiments, by chemical peptide synthesis procedures known in the art.

[0075] The term "monoclonal antibody" in this article refers to an antibody derived from a single clone (including any eukaryotic, prokaryotic, or phage clone), and is not limited to the method of antibody production.

[0076] The term "multispecific" in this article refers to having at least two antigen-binding sites, each of which binds to a different epitope of the same antigen or to a different epitope of a different antigen. Therefore, terms such as "bispecific," "trispecific," and "quadrispecific" refer to the number of different epitopes that an antibody / antigen binding molecule can bind to.

[0077] The term "valence" in this article refers to the presence of a specified number of binding sites in an antibody / antigen binding molecule. Therefore, the terms "monovalent," "divalent," "tetravalent," and "hexavalent" represent the presence of one, two, four, and six binding sites in an antibody / antigen binding molecule, respectively.

[0078] In this article, "full-length antibody," "intact antibody," and "complete antibody" are used interchangeably, referring to antibodies with structures that are substantially similar to those of natural antibodies.

[0079] In this document, "antigen-binding fragment" and "antibody fragment" are used interchangeably. They do not possess the complete structure of a full antibody, but only contain a portion or a local variant of the full antibody, which has the ability to bind antigens. For example, the "antigen-binding fragment" and "antibody fragment" can be single-domain antibodies.

[0080] The term "chimeric antibody" as used herein refers to an antibody having a variable sequence of an immunoglobulin derived from one source organism (such as rat, mouse, rabbit, or alpaca) and a constant region of an immunoglobulin derived from a different organism (such as human). Methods for producing chimeric antibodies are known in the art. See, for example, Morrison, 1985, Science 229(4719):1202-7; Oi et al., 1986, Bio Techniques 4:214-221; Gillies et al., 1985 J Immunol Methods 125:191-202; the above are incorporated herein by reference.

[0081] The term "humanized antibody" in this article refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase its homology with that of a human antibody. Typically, all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), while all or part of the non-CDR region (e.g., the variable region FR and / or constant region) is derived from a human immunoglobulin (receptor antibody). Humanized antibodies generally retain or partially retain the intended properties of the donor antibody, including but not limited to antigen specificity, affinity, reactivity, the ability to enhance immune cell activity, and the ability to strengthen the immune response.

[0082] The term "fully human antibody" in this document refers to an antibody having variable regions in which both the FR and CDR are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, that constant region is also derived from a human germline immunoglobulin sequence. Fully human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced through random or site-specific mutagenesis in vitro or through somatic mutations in vivo). However, "fully human antibody" in this document does not include antibodies in which a CDR sequence derived from another mammalian species (e.g., mouse) has been grafted onto a human frame sequence.

[0083] The term "variable region" in this article refers to the region in the antibody heavy or light chain involved in enabling antibody binding to antigens. "Heavy chain variable region" is used interchangeably with "VH" and "HCVR," and "light chain variable region" is used interchangeably with "VL" and "LCVR." The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies generally have similar structures, with each domain containing four conserved frame regions (FRs) and three hypervariable regions (HVRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain is sufficient to confer antigen-binding specificity. The terms "complementarity-determining region" and "CDR" are used interchangeably in this article. They generally refer to the hypervariable region (HVR) of the heavy chain variable region (VH) or light chain variable region (VL). This region is called the complementarity-determining region because it can form a precise complementarity with the antigenic epitope in its spatial structure. The heavy chain variable region CDR can be abbreviated as HCDR, and the light chain variable region CDR can be abbreviated as LCDR. The terms "framework region" and "FR region" are used interchangeably in this article. They refer to the amino acid residues in the antibody heavy chain variable region or light chain variable region other than the CDR. Typically, an antibody variable region consists of four FR regions and three CDR regions in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (see Kabat et al., Sequences of Protein of Immunological Interest, National Institute of Health, Bethesda, MD. 1987; incorporated herein by reference). For example, in this paper, CDR1-VH, CDR2-VH, and CDR3-VH refer to the first, second, and third CDRs of the variable region (VH) of the heavy chain, respectively. These three CDRs constitute the CDR combination (VHCDR combination) of the heavy chain (or its variable region); CDR1-VL, CDR2-VL, and CDR3-VL refer to the first, second, and third CDRs of the variable region (VL) of the light chain, respectively. These three CDRs constitute the CDR combination (VLCDR combination) of the light chain (or its variable region).

[0084] For further description of CDR, see Kabat et al., J. Biol. Chem., 252:6609-6616 (1977); Kabat et al., U.S. Department of Health and Human Services, “Sequences of proteins of immunological interest” (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273:927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45:3832-3839 (2008); Lefranc MP et al., Dev. Comp. Immunol., 27:55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001). The term “CDR” in this paper may be labeled and defined in a manner known in the art, including but not limited to the Kabat numbering system, the Chothia numbering system, or the IMGT numbering system, and the tools used may include but are not limited to the AbRSA website (http: / / cao.labshare.cn / AbRSA / cdrs.php), the abysis website (www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi), and the IMGT website (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi#results). The CDR in this paper includes overlaps and subsets of amino acid residues defined in different ways.

[0085] The term "Kabat numbering system" in this article usually refers to the immunoglobulin alignment and numbering system proposed by Elvin A. Kabat (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).

[0086] The term “Chothia numbering system” in this article usually refers to the immunoglobulin numbering system proposed by Chothia et al., which is a classic rule for identifying the boundaries of CDR regions based on the location of structural loop regions (see, for example, Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883).

[0087] The term "IMGT numbering system" in this article generally refers to the numbering system based on the international ImMunoGeneTics information system (IMGT) initiated by Lefranc et al., see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003.

[0088] The term "heavy chain constant region" in this document refers to the carboxyl-terminal portion of the antibody heavy chain, which does not directly participate in antibody-antigen binding but exhibits effector functions, such as interaction with the Fc receptor. It has a more conserved amino acid sequence compared to the variable domains of the antibody. A "heavy chain constant region" contains at least: a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, or variants or fragments thereof. "Heavy chain constant region" includes a "full-length heavy chain constant region" and a "heavy chain constant region fragment," the former having a structure substantially similar to the natural antibody constant region, while the latter includes only a portion of the full-length heavy chain constant region. Exemplarily, a typical "full-length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain antibody, it does not include the CH1 domain. Exemplarily, a typical "heavy chain constant region fragment" may be selected from either the Fc or CH3 domain.

[0089] The term "light chain constant region" in this article refers to the carboxyl terminus of the antibody light chain, which does not directly participate in the binding of the antibody to the antigen. The light chain constant region can be selected from the constant κ domain or the constant λ domain.

[0090] The term "Fc region" is used in this document to define a C-terminal region in an antibody heavy chain that contains at least a portion of a constant region. This term includes both native sequence Fc regions and variant Fc regions. Exemplarily, the human IgG heavy chain Fc region may extend from Cys226 or Pro230 to the C-terminus of the heavy chain. However, antibodies generated by host cells may undergo post-translational cleavage, removing one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Therefore, antibodies generated by host cells through the expression of a specific nucleic acid molecule encoding the full-length heavy chain may include the full-length heavy chain, or it may include a cleaved variant of the full-length heavy chain. This may be the case when the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbered according to the Kabat EU index). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present.

[0091] The IgG Fc region comprises IgG CH2 and IgG CH3 domains, and optionally, may also include a complete or partial hinge region, but not the CH1 domain. The “CH2 domain” of the human IgG Fc region typically extends from amino acid residue approximately at position 231 to amino acid residue approximately at position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or a variant CH2 domain. The “CH3 domain” comprises the residues at the C-terminus of the CH2 domain in the Fc region (i.e., from amino acid residue approximately at position 341 of the IgG to amino acid residue approximately at position 447). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having a “knob” introduced in one chain and a corresponding “hole” introduced in the other chain; see U.S. Patent No. 5,821,333, which is expressly incorporated herein by reference). As described herein, such variant CH3 domains can be used to promote heterodimerization of two dissimilar antibody heavy chains.

[0092] Unless otherwise specified herein, the amino acid residues in the Fc region or constant region are numbered according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0093] The term "conservative amino acid" in this document generally refers to amino acids that belong to the same class or have similar characteristics (e.g., charge, side chain size, hydrophobicity, hydrophilicity, main chain conformation, and rigidity). For example, the amino acids in each of the following groups belong to each other's conserved amino acid residues, and substitutions of amino acid residues within a group constitute substitutions of conserved amino acids:

[0094] 1) Alanine (A), Serine (S), Threonine (T);

[0095] 2) Aspartic acid (D), glutamic acid (E);

[0096] 3) Asparagine (N), glutamine (Q);

[0097] 4) Arginine (R), Lysine (K), Histidine (H);

[0098] 5) Isoleucine (I), leucine (L), methionine (M), valine (V); and

[0099] 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

[0100] The terms “percentage (%) sequence identity” and “percentage (%) identity” are used interchangeably herein and refer to the percentage of amino acid (or nucleotide) residues in a candidate sequence that are identical to those in a reference sequence after alignment to achieve maximum percentage sequence identity and the introduction of vacancies (if necessary) (e.g., for optimal alignment, vacancies may be introduced in one or both of the candidate and reference sequences, and non-homologous sequences may be ignored for comparison purposes). Alignment can be performed in a variety of ways well known to those skilled in the art for the purpose of determining percentage sequence identity, such as using publicly available computer software like BLAST, ALIGN, or Megalign (DNASTAIi) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the sequences being compared. For example, a reference sequence used for alignment against a candidate sequence may show that the candidate sequence exhibits sequence identity from 50% to 100% across the full length of the candidate sequence or selected portions of consecutive amino acid (or nucleotide) residues of the candidate sequence. The length of a candidate sequence for comparison purposes can be at least 30% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) of the length of a reference sequence. Molecules are considered identical at that position when a position in a candidate sequence is occupied by the same amino acid (or nucleotide) residue as the corresponding position in the reference sequence.

[0101] The term "chimeric antigen receptor (CAR)" in this article refers to an artificial cell surface receptor modified to be expressed on immune effector cells and specifically bind to antigens, comprising at least (1) an extracellular antigen-binding domain, such as a variable heavy or light chain of an antibody, (2) a transmembrane domain that anchors the CAR into immune effector cells, and (3) an intracellular signal transduction domain. CARs can redirect T cells and other immune effector cells to selected targets, such as cancer cells, in a non-MHC-restricted manner using the extracellular antigen-binding domain.

[0102] The term "nucleic acid" in this document includes any compound and / or substance comprising a polymer containing nucleotides. Each nucleotide consists of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Typically, nucleic acid molecules are described by the sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is typically represented as 5′ to 3′. In this document, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and polymers containing mixtures of two or more of these molecules. Nucleic acid molecules can be linear or circular. Furthermore, the term nucleic acid molecule includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Moreover, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derived sugar or phosphate backbones or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as carriers for the direct expression of the antibodies of the present invention in vitro and / or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) carriers can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA carrier and / or the expression of the encoded molecule, thereby allowing the mRNA to be injected into a subject to generate antibodies in vivo (see, for example, Stadler et al., Nature Medicine 2017, published online June 12, 2017, doi: 10.1038 / nm.4356 or EP 2 101 823 B1). “Isolated” nucleic acids herein refer to nucleic acid molecules that have been separated from components of their native environment. Isolated nucleic acids include nucleic acid molecules contained in cells that typically contain such molecules but are present outside the chromosome or at a chromosomal location different from their native chromosomal location.

[0103] The term "vector" in this document includes nucleic acid vectors, such as DNA vectors (e.g., plasmids), RNA vectors, viruses, or other suitable replicons (e.g., viral vectors). Various vectors have been developed for delivering polynucleotides encoding foreign proteins into prokaryotic or eukaryotic cells. The expression vectors of the present invention contain polynucleotide sequences and additional sequence elements, for example, for expressing proteins and / or integrating these polynucleotide sequences into the genome of mammalian cells. Some vectors that can be used to express the antibodies and antibody fragments of the present invention include plasmids containing regulatory sequences (e.g., promoter and enhancer regions) that guide gene transcription. Other useful vectors for expressing antibodies and antibody fragments contain polynucleotide sequences that enhance the translation rate of these genes or improve the stability or nuclear export of mRNA produced by gene transcription. These sequence elements include, for example, 5' and 3' untranslated regions, internal ribosome entry sites (IRES), and polyadenylation signal sites to guide efficient transcription of the gene carried on the expression vector. The expression vectors of the present invention may also contain polynucleotides encoding markers for selecting cells containing such vectors. Examples of suitable markers include genes encoding resistance to antibiotics such as ampicillin, chloramphenicol, kanamycin, or norsocrine.

[0104] The term "host cell" in this article refers to a cell in which foreign nucleic acids have been introduced, including the progeny of such cells. Host cells include "transformers" and "transformed cells," which include primary transformed cells and their progeny, regardless of the number of passages. Progeny may not be identical to parental cells in their nucleic acid contents and may contain mutations. This article includes mutant progeny with the same function or biological activity as those screened or selected in the initially transformed cells.

[0105] The steps of transforming host cells with recombinant DNA as described in this invention can be performed using conventional techniques well known to those skilled in the art. The resulting transformants can be cultured using conventional methods and express the polypeptide encoded by the gene of this invention. Depending on the host cells used, the culture medium can be selected from various conventional culture media. The host cells are cultured under conditions suitable for host cell growth.

[0106] The term "pharmaceutical composition" as used herein refers to a formulation which is present in a form that allows for the effective biological activity of the active ingredient contained therein, and which does not contain any additional ingredients that would have unacceptable toxicity to a subject administering the pharmaceutical composition.

[0107] The terms “subject,” “object,” and “patient” in this document refer to an organism that receives treatment for a specific disease or condition (such as cancer or an infectious disease) as described herein. Examples of objects and patients include mammals receiving treatment for diseases or conditions (such as proliferative disorders like cancer or infectious diseases), such as humans, primates, pigs, goats, rabbits, hamsters, cats, dogs, guinea pigs, members of the Bovidae family (such as domestic cattle, bison, buffalo, elk, and yaks), cattle, sheep, horses, and bison.

[0108] The term "treatment" in this article refers to surgical or therapeutic treatment aimed at preventing, slowing (reducing) undesirable physiological changes or lesions in the treated individual, such as the progression of proliferative disorders (e.g., cancer or infectious diseases). Beneficial or desired clinical outcomes include, but are not limited to, symptom relief, disease severity reduction, disease stability (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of disease status, and remission (whether partial or complete), whether detectable or undetectable. Individuals requiring treatment include those already suffering from the condition or disease, those susceptible to the condition or disease, or those intending to prevent the condition or disease. When the terms slowing, reducing, weakening, mitigating, or alleviating are used, they also include elimination, disappearance, and non-occurrence.

[0109] The term "effective dose" in this document refers to the amount of a therapeutic agent, when administered alone or in combination with another therapeutic agent to cells, tissues, or subjects, that is effective in preventing or alleviating symptoms of a disease or the progression of that disease. "Effective dose" also refers to the amount of a compound sufficient to relieve symptoms, such as treating, curing, preventing, or alleviating an associated medical condition, or increasing the rate at which such symptoms are treated, cured, prevented, or alleviated. When an active ingredient is administered to an individual alone, the therapeutically effective dose refers to that ingredient alone. When a combination is used, the therapeutically effective dose refers to the combined amount of active ingredients that produce a therapeutic effect, regardless of whether they are administered in combination, consecutively, or simultaneously.

[0110] The term "cancer" in this document refers to or describes a physiological condition in mammals characterized by unregulated cell growth. This definition includes both benign and malignant cancers. The term "tumor" or "tumor" in this document refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer" and "tumor" are not mutually exclusive when used in this document. Attached Figure Description

[0111] The foregoing and other aspects of the invention will be clearly illustrated below with reference to the detailed description and accompanying drawings. The accompanying drawings are provided to illustrate some preferred embodiments of the invention; however, it is to be understood that the invention is not limited to the specific embodiments disclosed.

[0112] Figure 1 SDS-PAGE results of human CD33-V-his and CD33-C2-his protein samples using reducing and non-reducing gels: 1-hCD33-V-his (non-reducing); 2-hCD33-V-his (reducing); 3-hCD33-C2-his (non-reducing); 4-hCD33-C2-his (reducing); M-marker.

[0113] Figure 2A ELISA was used to detect the binding reaction between the control antibody and human CD33-his protein.

[0114] Figure 2B ELISA was used to detect the binding reaction between the control antibody and human CD33-V-his protein.

[0115] Figure 2C ELISA was used to detect the binding reaction between the control antibody and human CD33-C2-his protein.

[0116] Figure 3 FACS results of detecting CD33 expression in U937 cells using SGN-33 antibody.

[0117] Figure 4 FACS screening results of CHO-K1 cells transfected with human CD33 protein.

[0118] Figure 5 FACS screening results of HEK293T cells transfected with monkey CD33 protein.

[0119] Figure 6A ELISA was used to detect the serum antibody titer of alpacas after immunization with human CD33 protein.

[0120] Figure 6B FACS detection of serum antibody titers in alpacas after immunization with human CD33 protein.

[0121] Figure 7A , 7B ELISA was used to detect the binding reaction between VHH antibody and human CD33-his protein.

[0122] Figure 8A , 8B FACS was used to detect the binding reaction between VHH antibody and CHO-K1-human CD33.

[0123] Figure 8C , 8D FACS was used to detect the binding reaction between VHH antibody and U937.

[0124] Figure 9A , 9B ELISA was used to detect the binding reaction between VHH antibody and mouse CD33-His protein.

[0125] Figure 9C , 9D ELISA was used to detect the binding reaction between VHH antibody and monkey CD33-His protein.

[0126] Figure 10A , 10B FACS was used to detect the binding reaction of VHH antibody with HEK293T-monkey CD33.

[0127] Figure 11A , 11C ELISA was used to detect the binding reaction between VHH antibody and human CD33-V-his protein.

[0128] Figure 11B , 11D The binding reaction between VHH antibody and human CD33-C2-his protein was detected by ELISA.

[0129] Figure 12A , 12B A competitive ELISA method was used to detect the inhibition rate between VHH antibodies.

[0130] Figure 13A , 13B VHH antibody competes with Biotin-C33B904 ELISA.

[0131] Figure 14 Classification of antigenic epitopes of VHH antibodies.

[0132] Figures 15A-15E The binding reaction between the VHH humanized antibody and the human CD33-his protein was detected by ELISA.

[0133] Figures 16A-16E FACS was used to detect the binding reaction between VHH humanized antibody and CHO-K1-human CD33.

[0134] Figures 17A-17E FACS was used to detect the binding reaction between VHH humanized antibody and U937.

[0135] Figures 18A-18E The binding reaction between the VHH humanized antibody and mouse CD33-his protein was detected by ELISA.

[0136] Figures 18F-18J The binding reaction between the VHH humanized antibody and the monkey CD33-his protein was detected by ELISA.

[0137] Figures 19A-19E FACS was used to detect the binding reaction between VHH humanized antibody and HEK293T-monkey CD33.

[0138] Figures 20A-20E The binding reaction between the VHH humanized antibody and the human CD33-V-his protein was detected by ELISA.

[0139] Figures 20F to 20J The binding reaction between the VHH humanized antibody and the human CD33-C2-his protein was detected by ELISA. Detailed Implementation

[0140] The present invention will now be described in detail with reference to embodiments and accompanying drawings. The accompanying drawings are provided to illustrate some preferred embodiments of the invention; however, it is to be understood that the invention is not limited to the specific embodiments disclosed or should not be considered a limitation on the scope of the invention. Unless otherwise specified, specific conditions in the embodiments are performed under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used, unless otherwise specified, are all commercially available conventional products.

[0141] Example 1: Preparation of control antibody and CD33 protein

[0142] 1.1 Preparation of control antibody

[0143] The CD33 protein has a conserved V-set immunoglobulin-like domain and a variable C2-set domain extracellularly. SGN-33 and C33B904 are antibodies that recognize human CD33. The antigen-binding epitope of SGN-33 is located in the V-set domain, and the antigen-binding epitope of C33B904 is located in the C2-set domain. The heavy chain and light chain variable region sequences of SGN-33 are obtained according to patent US 9453046, and the heavy chain and light chain variable region sequences of C33B904 are obtained according to patent US20190382481A1. The VH and VL of the human CD33 antibody SGN-33 and the human IgG1 Fc are linked in order from the N-terminus to the C-terminus, with VH and VL linked by three GGGGS linkers, forming the scFv-hFc form; the VH and VL of the human CD33 antibody C33B904 are used to form the complete human IgG1 antibody form. The corresponding amino acid sequence information is shown in Table 1 below. Italics and underlines indicate the antibody variable region sequence. The corresponding nucleotide sequences were cloned into the pTT5 vector (completed by Universal Biosystems (Anhui) Co., Ltd.) and plasmids were prepared according to established standard molecular biology methods. For specific methods, please refer to Sambrook, J., Fritsch, EF, and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press). The expression vector was transiently transfected into HEK293E cells (purchased from Suzhou Yiyan Biotechnology Co., Ltd.) according to the PEI (purchased from Polysciences, catalog number: 24765-1) instructions, and FreeStyle was used. TM Cells were cultured continuously at 37°C for 5 days using 293 (Thermofisher Scientific, catalog number: 12338018). Cell components were removed by centrifugation, yielding a culture supernatant containing antibodies. This supernatant was loaded onto a Protein A chromatography column (AT Protein ADiamond packing material and BXK16 / 26 column were purchased from BorgL, catalog numbers: AA0273 and B-1620, respectively). The column was washed with PBS phosphate buffer (pH 7.4), followed by washing with 20 mM PB and 1 M NaCl (pH 7.2). Finally, elution was performed with citrate buffer (pH 3.4). The Fc-tagged antibodies eluted from the Protein A column were collected, neutralized with 1 / 10 volume of 1 M Tris (pH 8.0), and dialyzed overnight with PBS at 4°C. The dialyzed protein was aseptically filtered through a 0.22 μm filter and aliquoted for storage at -80°C.

[0144] Table 1. Sequence information of anti-human CD33 antibodies SGN-33 and C33B904.

[0145]

[0146] 1.2 Preparation of human CD33-V-his and human CD33-C2-his proteins

[0147] The extracellular domain (ECD) amino acid sequence Asp 18-His259 protein encoding human CD33 was purchased from ACROBiosystems (catalog number: CD3-H5226) and named human CD33-his.

[0148] The nucleotide sequences encoding the his-tagged human CD33-V domain Pro19-Ser135 (SEQ ID NO: 4) and C2 domain Pro145-Gln228 (SEQ ID NO: 5) were cloned into the pTT5 vector (completed by General Biosystems (Anhui) Co., Ltd.), and plasmids were prepared according to established standard molecular biology methods. The corresponding amino acid sequence information is shown in Table 2 below. For specific methods, please refer to Sambrook, J., Fritsch, EF, and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press). HEK293E cells (purchased from Suzhou Yiyan Biotechnology Co., Ltd.) were transiently transfected (PEI, Polysciences, catalog number: 24765-1) and expanded using a FreeStyle™ 293 (Thermofisher Scientific, catalog number: 12338018) at 37°C. After 6 days, the cell culture medium was collected, and cell components were removed by centrifugation to obtain a culture supernatant containing the V and C2 domains of human CD33 protein. The culture supernatant was then loaded onto a HisTrap nickel affinity chromatography column. TMExcel (GE Healthcare, catalog number: GE17-3712-06) was used, and UV absorbance (A280nm) changes were monitored using a UV detector. After sample loading, the nickel affinity chromatography column was washed with 20 mM PB and 0.5 M NaCl (pH 7.4) until the UV absorbance returned to baseline. Then, gradient elution (2%, 4%, 8%, 16%, 50%, 100%) was performed using buffer A: 20 mM PB, 0.5 M NaCl (pH 7.4) and buffer B: 20 ​​mM PB, 0.5 M NaCl, 500 mM imidazole. The His-tagged human CD33 protein eluted from the nickel affinity chromatography column was collected and dialyzed overnight at 4°C with PBS phosphate buffer (pH 7.4). After dialysis, the protein was aseptically filtered through a 0.22-micron filter membrane and then aliquoted and stored at -80°C to obtain purified human CD33 protein. The target bands of the samples were detected using SDS-PAGE with both reducing and non-reducing gels. Figure 1 As shown.

[0149] The CD33 protein was detected by ELISA using positive control antibodies that recognize different epitopes. The negative control antibody, hIgG1, was anti-hel-hIgG1 (purchased from Baiying, catalog number: B117901), an antibody against Hen Egg Lysozyme. The detection results are shown in Tables 3-5 and... Figure 2A-2C As shown, both SGN-33 and C33B904 can bind to human CD33-his protein. SGN-33 can bind to human CD33-V-his protein, while C33B904 can bind to human CD33-C2-his protein. The detection results are consistent with the binding epitopes reported in the literature, indicating that proteins with the above-mentioned binding activities have been prepared.

[0150] Table 2. Amino acid sequences of the extracellular region, V-domain, and C2-domain of human CD33 protein.

[0151]

[0152] Table 3. ELISA detection of the binding reaction between the control antibody and human CD33-his protein

[0153]

[0154] Table 4. ELISA detection of the binding reaction between the control antibody and human CD33-V-his protein

[0155]

[0156] Table 5. ELISA detection of the binding reaction between the control antibody and human CD33-C2-his protein

[0157]

[0158] Example 2: Identification of endogenous expression cell lines and preparation of overexpression cell lines

[0159] 2.1 Identification of cell lines expressing endogenous CD33

[0160] U937 cells were cultured in T-25 cell culture flasks to the logarithmic growth phase. After centrifugation, the supernatant was discarded, and the cell pellet was washed twice with PBS. The cells were incubated for 15 minutes with buffer containing human Fc Block (BD, catalog number: 564220). SGN-33 antibody was used as the primary antibody, and APC-labeled secondary antibody (Biolegend, catalog number: 409306) was used. The results were detected and analyzed using FACS (FACSCanto™, BD). The analytical results are shown in Table 6. Figure 3 As shown, U937 cells can bind to SGN-33.

[0161] Table 6. FACS results of endogenous cell line U937 cells

[0162]

[0163] 2.2 Preparation of CHO-K1 stable human CD33 monoclonal cell line

[0164] The nucleotide sequence encoding the full-length amino acid sequence of human CD33 (NCBI: XP_011525834.1) was cloned into the pcDNA3.1 vector and plasmids were prepared (by General Biosystems (Anhui) Co., Ltd.). Plasmid transfection was performed on the CHO-K1 cell line (purchased from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences). The 3000 Transfection Kit (Invitrogen, catalog number: L3000-015) was used to selectively culture cells for 2 weeks in DMEM / F12 medium containing 10 μg / ml puromycin and 10% (w / w) fetal bovine serum. Positive monoclonal cells were sorted into 96-well plates using SGN-33 antibody as the primary antibody and Alexa Fluor 647-labeled secondary antibody (Jackson, catalog number: 109605088) on a FACSAriaII flow cytometer (BD Biosciences) and incubated at 37°C with 5% (v / v) CO2. After approximately 2 weeks, a subset of monoclonal cells were selected for amplification. The amplified clones were screened by flow cytometry. Cell lines with good growth, high fluorescence intensity, and monoclonal cells were selected for further expansion and cryopreservation in liquid nitrogen.

[0165] The specific selection results are shown in Table 7 and... Figure 4 As shown, the IgG subtype control is the human IgG control. Table 7 illustrates that a series of CHO-K1 monoclonal cell lines expressing human CD33 have been obtained. Figure 4 In the graph, the horizontal axis represents cell fluorescence intensity, and the vertical axis represents cell number. Figure 4 The results indicate that CHO-K1-humanCD33B8, CHO-K1-humanCD33B11, and CHO-K1-humanCD33C8 are cell lines that express human CD33 at a high level.

[0166] Table 7. FACS results of human CD33 protein in CHO-K1 stable cell lines

[0167]

[0168] 2.3 Preparation of HEK293T stable transgenic monkey CD33 cell line

[0169] The nucleotide sequence encoding the full-length amino acid sequence of monkey CD33 (NCBI: XP_014980179.1) was cloned into the pcDNA3.1 vector (purchased from Thermo Fisher Scientific) and a plasmid was prepared. This plasmid was then used on the HEK293T cell line. After plasmid transfection with HD (Promega, catalog number: #E2311), cells were selectively cultured for 2 weeks in DMEM medium containing 10 μg / ml puromycin and 10% (w / w) fetal bovine serum. Subcloning was performed in 96-well plates using limiting dilution and the plates were incubated at 37°C with 5% (v / v) CO2. After approximately 2 weeks, a portion of the polyclonal wells were amplified into 6-well plates. NB147, a polyclonal antibody obtained from the serum of alpacas immunized with human CD33 protein (prepared in Example 3), was used as a positive control. The amplified clones were screened by flow cytometry, and polyclonal cell lines with good growth and high fluorescence intensity were selected for further expansion and cryopreservation in liquid nitrogen, as shown in Table 8. Figure 5 As shown, flow cytometry analysis of the HEK293T cell line revealed a single positive cell peak overexpressing monkey CD33 after puromycin screening, which can be used to detect the cross-activity of antibodies.

[0170] Table 8. FACS results of monkey CD33 protein in HEK293T stable cell lines

[0171]

[0172] Example 3: Screening for VHH, a single-domain antibody targeting CD33

[0173] 3.1 Immunity and serum titer testing of alpacas

[0174] Two llamas were selected for immunization. Each llama was immunized four times, with each immunization occurring three weeks apart. The first and second immunizations used human CD33(Asp18-His259)-Pol-his protein purchased from ACROBiosystems (catalog number: CD3-H5226). The third immunization used human CD33(Asp18-His259)-Fc(Pro100-Lys330) protein purchased from ACROBiosystems (catalog number: CD3-H5257). The fourth immunization used CHO-K1-human CD33-B8 prepared in Example 2. Peripheral blood was collected after the third and fourth immunizations, and serum was separated. The antibody titer and specificity against human CD33 (hCD33) in the serum were detected by enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FACS). The results are as follows: Figures 6A-6B As shown in Table 9, the serum of alpacas immunized with human CD33 showed varying degrees of binding to the immunogen, exhibiting an antigen-antibody reaction, with the highest dilution around 5.9 million. The blank control was 1% (w / w) BSA, and the batches referred to were alpaca serum seven days after the third (TB2, 2nd-bleeding) and fourth (TB3, 3rd-bleeding) immunizations. The data in the table are OD450nm values. NB147 alpaca serum can bind to mouse CD33 protein and can be used as a positive control antibody in subsequent cross-reactivity experiments.

[0175] Table 9. ELISA detection of alpaca serum antibody titers after hCD33 protein immunization.

[0176]

[0177]

[0178] 3.2 Library Construction

[0179] Peripheral blood (100 mL) was collected from alpacas after seven immunizations. Peripheral blood cells (PBMCs) were isolated using lymphocyte separation medium, and total RNA was extracted using RNAiso Plus reagent (Takara, catalog number: #9108 / 9109). PrimeScript was used to analyze the RNA. TM The II 1st Strand cDNA Synthesis Kit (Takara, catalog number: 6210A) reverse transcribes extracted RNA into cDNA. Nested PCR is then used to amplify the variable region nucleic acid fragment encoding the heavy chain antibody.

[0180] First round of PCR:

[0181] Upstream primer: CTTGGTGGTCCTGGCTGC (SEQ ID NO: 6)

[0182] Downstream primer: GGTACGTGCTGTTGAACTGTTCC (SEQ ID NO: 7)

[0183] Second round of PCR:

[0184] Using the first-round PCR product as a template,

[0185] Upstream primer (SEQ ID NO: 8):

[0186]

[0187] Downstream primer-1 (SEQ ID NO: 9):

[0188]

[0189] Downstream primer-2 (SEQ ID NO: 10):

[0190]

[0191] The target single-domain antibody nucleic acid fragment was recovered and cloned into the phage display vector pcomb3XSS (from Sichuan Apak Biotechnology Co., Ltd.) using the restriction endonuclease SfiI (NEB, catalog number: R0123S). The product was then electroporated into *E. coli* electroporated competent cells TG1 (from Sichuan Apak Biotechnology Co., Ltd.) to construct a phage display library targeting CD33, and the library was validated. The library size was calculated to be 3.4 × 10⁻⁶ cells after serial dilution plating. 9 To determine the insertion rate of the library, 48 clones were randomly selected for colony PCR. The results showed an insertion rate of 100%.

[0192] 3.3 Screening of CD33 single-domain antibodies

[0193] The plates were coated with 0.5 μg / well of human CD33-Llama-Fc fusion protein (ACROBiosystems, catalog number: CD3-H5259) and incubated overnight at 4°C. The next day, the plates were blocked with 3% BSA-PBS at 37°C for 1 h. Then, 100 μl of phage display library was added and incubated at 37°C for 1 h. The plates were then washed 6 times with PBST and 2 times with PBS to remove unbound phages. Finally, 100 μL of Gly-HCl elution buffer was added to elute phages that specifically bind to CD33, thereby enriching positive clones.

[0194] 3.4 Phage enzyme-linked immunosorbent assay (ELISA) for screening specific single positive clones

[0195] After selection, the obtained CD33-positive phages were used to infect blank *E. coli* and plated. Ninety-six single colonies were then selected and amplified. Plates were coated with CD33-his protein and incubated overnight at 4°C. The phage culture supernatant was added, and the plates were incubated at 37°C for 1 hour. After washing, TMB chromogenic buffer was added, and the optical density was measured at 450 nm. CD33-his positive clones were selected for sequencing. The sequencing results were analyzed using MOE software. A phylogenetic tree was constructed based on the amino acid sequence of the VHH-encoded protein. Sequences that were close to each other on the phylogenetic tree were removed based on sequence similarity, resulting in 18 clones. The CDRs of these clones were analyzed using KABAT, Chothia, or IMGT software, and the corresponding sequence information is shown in Table 10. Subsequently, single-domain antibody production and identification were performed.

[0196] Table 10. Information on VHH single-domain antibody sequences obtained through screening

[0197]

[0198]

[0199]

[0200]

[0201] Example 4: Preparation of VHH single-domain antibody

[0202] 4.1 Expression and purification of VHH single-domain antibody

[0203] The VHH variable region sequence was recombined into the expression vector BI3.4-huIgG1, which contains a signal peptide and human IgG1 Fc (human IgG1 Fc sequence as SEQ ID NO: 191, hinge region sequence as SEQ ID NO: 192), by Taizhou Baiying Biotechnology Co., Ltd. Plasmids were prepared according to established standard molecular biology methods, the specific methods of which can be found in Sambrook, J., Fritsch, EF, and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press). The expression vector was transiently transfected into HEK293E cells (purchased from Suzhou Yiyan Biotechnology Co., Ltd.) according to the PEI (purchased from Polysciences, catalog number: 24765-1) instructions, and the cells were continuously cultured at 37°C for 5 days using FreeStyle™ 293 (Thermofisher Scientific, catalog number: 12338018). Cell components were removed by centrifugation, and culture supernatant containing VHH single-domain antibody was obtained. The culture supernatant was loaded onto a protein A chromatography column (the AT Protein A Diamond packing material and the BXK16 / 26 chromatography column were both purchased from BorgL, catalog numbers: AA0273 and B-1620, respectively). The column was washed with PBS phosphate buffer (pH 7.4), followed by washing with 20 mM PB, 1 M NaCl, pH 7.2, and finally eluted with citrate buffer (pH 3.4). The Fc-tagged antibody eluted from the protein A chromatography column was collected, neutralized with 1 / 10 volume of 1 M Tris (pH 8.0), and dialyzed overnight with PBS at 4°C. The dialyzed protein was aseptically filtered through a 0.22 μm filter and aliquoted for storage at -80°C.

[0204] The sequence of human IgG1Fc (SEQ ID NO: 191):

[0205]

[0206] Hinge region sequence (SEQ ID NO:192): EPKSADKTHTCPPCP

[0207] Example 5: Identification of VHH single-domain antibodies

[0208] 5.1 Enzyme-linked immunosorbent assay (ELISA) to detect the binding of VHH antibody to CD33 protein.

[0209] To detect the binding activity of VHH-Fc to human CD33 protein, human CD33-his protein (purchased from ACROBiosystems, catalog number: CD3-H5226) was diluted to a final concentration of 2 μg / mL with PBS, and then 100 μl was added to each well of a 96-well ELISA plate. The plate was sealed with plastic film and incubated overnight at 4°C. The next day, the plate was washed twice with PBS, and blocking buffer [PBS + 2% (w / w) BSA] was added and blocked at room temperature for 2 hours. The blocking buffer was discarded, and 50 μl of serially diluted 100 nM VHH-Fc antibody or negative control antibody was added to each well. After incubation at 37°C for 2 hours, the plate was washed three times with PBS. HRP (horseradish peroxidase)-labeled secondary antibody (purchased from Sigma, catalog number: A0170) was added, and the plate was incubated at 37°C for 1 hour, followed by washing five times with PBS. 50 μl of TMB substrate was added to each well. After incubating at room temperature for 10 minutes, add 50 μl of stop solution (1.0 N HCl) to each well. Read the OD450 nm value using an ELISA plate reader (Multimode Plate Reader, EnSight, Perkin Elmer). The ELISA results for VHH-Fc and hCD33-his are as follows: Figure 7A , 7B As shown in Tables 11 and 12, the purified antibodies can bind to human CD33 protein at the ELISA level. The IgG control is hIgG1, and the data in the tables represent OD450nm values.

[0210] Table 11. ELISA detection of the binding reaction between VHH-Fc antibody and human CD33 protein

[0211]

[0212]

[0213] Table 12. ELISA detection of the binding reaction between VHH-Fc antibody and human CD33 protein

[0214]

[0215] 5.2 Flow cytometry (FACS) assay to detect the binding of antibodies to cells expressing different CD33.

[0216] The desired cells were cultured in T-75 cell culture flasks to the logarithmic growth phase. For adherent CHO-K1 cells, the culture medium was aspirated, and the cells were washed twice with PBS buffer. The cells were then digested with trypsin, and after digestion, washed twice with PBS buffer. For suspension U937 cells, the supernatant was discarded by centrifugation, and the cell pellet was washed twice with PBS and incubated for 15 minutes with buffer containing human Fc Block (purchased from BD, catalog number: 564220). After cell counting, the cell pellet was resuspended in [PBS + 2% (w / w) BSA] blocking solution to a concentration of 2 × 10⁻⁶ cells / mL. 6 Cells were added at a rate of 50 μl per well to a 96-well FACS plate, along with 50 μl of VHH-Fc antibody test sample per well. The plates were incubated on ice for 2 hours. After washing three times with PBS buffer, 50 μl of Alexa Flour 488-labeled secondary antibody (Invitrogen, catalog number A-11013) was added to each well, and the plates were incubated on ice for 1 hour. After washing five times with PBS buffer, the cells were detected and analyzed using FACS (FACS Canto™, BD). The mean fluorescence intensity (MFI) of the cells was obtained. The data were then analyzed using software (GraphPad Prism8) to perform data fitting and calculate EC50. The analysis results are shown in Tables 13 and 14. Figures 8A-8D As shown, VHH antibodies can bind to human CD33 protein on the surface of U937 cells and CHO-K1-hCD33-B8 cells. Figures 8A-8D ), but does not bind to negative cells.

[0217] Table 13. FACS detection of the binding reaction of VHH-Fc antibody with U937 and CHO-K1-human CD33 cells

[0218]

[0219]

[0220] Table 14. FACS detection of the binding reaction of VHH-Fc antibody with U937 and CHO-K1-human CD33 cells

[0221]

[0222] Example 6: Detection of species cross-binding activity of VHH-Fc antibody

[0223] 6.1 ELISA detection of the binding of VHH-Fc antibody to CD33 protein of different species

[0224] To detect the cross-species activity of the VHH-Fc antibody, commercially available mouse CD33 (Sino Biological, catalog number: 90303-C08H) and monkey CD33 (Sino Biological, catalog number: 50712-M08H) were coated onto ELISA plates, and ELISA detection was performed according to the method in Example 5.1. The ELISA results of VHH-Fc antibody and mouse CD33 are as follows: Figures 9A-9B As shown in Tables 15 and 16, the ELISA results of VHH-Fc antibody and monkey CD33 are as follows: Figure 9C , 9D As shown in Tables 17 and 18. The IgG control is hIgG1, and the data in the tables are OD450nm values. Only S006-NB146-69 binds well to mouse CD33 protein, while S006-NB146-132 and S006-NB146-173 bind weakly to mouse CD33 protein. Except for S006-NB146-60 and S006-NB147-225, VHH-Fc can bind to monkey CD33 protein. Figure 9D SGN-33 in the middle does not bind to the monkey CD33 protein.

[0225] Table 15. ELISA detection of the binding reaction between VHH-Fc antibody and mouse CD33 protein

[0226]

[0227] Table 16. ELISA detection of the binding reaction between VHH-Fc antibody and mouse CD33 protein

[0228]

[0229] *: NB147 alpaca serum is serially diluted 10-fold starting from 1:100.

[0230] Table 17. ELISA detection of the binding reaction between VHH-Fc antibody and monkey CD33 protein

[0231]

[0232]

[0233] Table 18. ELISA detection of the binding reaction between VHH-Fc antibody and monkey CD33 protein

[0234]

[0235] 6.2 FACS detection of the binding of VHH-Fc antibody to recombinant monkey CD33 cell line

[0236] The HEK293T-monkey CD33 cell line was subjected to FACS detection and data analysis according to the method in Example 5.2. The analysis results are shown in Tables 19 and 20. Figures 10A-10B As shown, except for S006-NB147-60 and S006-NB147-225, the remaining VHH-Fc antibodies all showed binding activity with HEK293T-monkey CD33 cells, but no binding activity with HEK293T cells.

[0237] Table 19. FACS detection of the binding reaction between VHH antibody and HEK293T-monkey CD33 cell line

[0238]

[0239]

[0240] Table 20. FACS detection of the binding reaction between VHH antibody and HEK293T-monkey CD33 cell line

[0241]

[0242] Example 7: CD33 antibody affinity assay

[0243] 7.1 Determination of the affinity between VHH-Fc antibody and human CD33-his protein

[0244] Human CD33 VHH-Fc antibody was captured using a Protein A chip (GE Helthcare; 29-127-558). Samples and run buffer were prepared as HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P2O) (GE Healthcare; BR-1006-69). The flow cell was set to 25°C. The sample block was set to 16°C. Both were pretreated with run buffer. In each cycle, the antibody was first captured using the Protein A chip, followed by the injection of a single concentration of CD33 antigen protein. The binding and dissociation of the antibody and antigen protein were recorded. Finally, the chip was regenerated using Glycine pH 1.5 (GE Helthcare; BR-1003-54). Binding was measured by injecting different concentrations of recombinant human CD33-his into the solution for 240 seconds at a flow rate of 30 μL / min, starting at 200 nM and diluted 1:1 for a total of 5 concentrations. The dissociation phase was monitored for up to 600 seconds, triggered by switching from the sample solution to the run buffer. The surface was regenerated by washing with 10 mM glycine solution (pH 1.5) at a flow rate of 30 μL / min for 30 seconds. Bulk refractive index differences were corrected for by subtracting the response obtained from the goat anti-human Fc surface. Blank injections (=dual reference) were also subtracted. The Langmuir 1:1 model was used to calculate apparent KD and other kinetic parameters. The binding rate (Kon), dissociation rate (Koff), and binding affinity (KD) of the VHH-Fc antibody to human CD33-his protein are shown in Tables 21 and 22, with antibodies C33B904 and SGN-33 serving as positive controls. As shown in Tables 21 and 22, the VHH-Fc antibody has a better affinity for human CD33 than 1.40E-07M.

[0245] Table 21. SPR (biacore) assay for affinity between VHH-Fc antibody and human CD33

[0246] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-1 1.95E+05 4.38E-05 2.24E-10 S006-NB146-3 2.49E+03 6.28E-06 2.52E-09 S006-NB146-17 1.19E+05 2.18E-05 1.83E-10 S006-NB146-20 4.12E+05 3.77E-04 9.17E-10 S006-NB146-39 1.79E+05 2.95E-05 1.65E-10 S006-NB146-40 1.46E+03 1.23E-05 8.39E-09 S006-NB146-46 1.98E+05 3.39E-05 1.71E-10 S006-NB146-60 1.49E+05 1.50E-04 1.01E-09 S006-NB146-132 1.31E+05 6.96E-05 5.31E-10 S006-NB147-225 2.93E+04 5.29E-04 1.80E-08 C33B904 2.60E+05 4.08E-05 1.57E-10 SGN-33 7.02E+05 5.57E-03 7.93E-09

[0247] Table 22. SPR (biacore) assay for the affinity of VHH-Fc antibody to human CD33

[0248] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-16 6.01E+04 2.24E-03 3.73E-08 S006-NB147-25 1.41E+05 1.58E-04 1.12E-09 S006-NB146-69 6.71E+04 3.26E-03 4.86E-08 S006-NB146-139 2.97E+05 4.01E-03 1.35E-08 S006-NB146-150 5.22E+04 7.33E-03 1.40E-07 S006-NB146-173 7.25E+04 1.72E-03 2.38E-08 S006-NB146-181 5.54E+04 2.87E-03 5.18E-08 S006-NB147-220 1.81E+05 4.97E-04 2.75E-09 C33B904 4.79E+05 7.44E-05 1.55E-10

[0249] 7.2 Affinity determination of VHH-Fc with monkey CD33-his protein

[0250] The affinity of VHH-Fc antibody to monkey CD33 (Sino Biological, catalog number: 50712-M08H) protein was determined according to the method in Example 7.1. As shown in Tables 23 and 24, S006-NB146-20, S006-NB146-39, and S006-NB146-46 showed better affinity to monkey CD33 than 1.0E-09M.

[0251] Table 23. SPR (biacore) assay for affinity between VHH-Fc antibody and monkey CD33

[0252] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-1 2.49E+05 2.68E-04 1.08E-09 S006-NB146-3 1.08E+04 1.63E-04 1.51E-08 S006-NB146-17 1.13E+05 1.28E-04 1.13E-09

[0253] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-20 9.02E+05 4.95E-04 5.48E-10 S006-NB146-39 5.90E+05 6.98E-05 1.18E-10 S006-NB146-40 1.39E+03 2.56E-04 1.83E-07 S006-NB146-46 5.84E+05 9.36E-05 1.60E-10 S006-NB146-132 2.16E+05 3.62E-04 1.67E-09 C33B904 1.29E+06 6.32E-04 4.92E-10

[0254] Table 24. SPR (biacore) assay for affinity between VHH-Fc antibody and monkey CD33.

[0255] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-16 1.40E+05 1.54E-02 1.10E-07 S006-NB147-25 4.06E+05 2.34E-03 5.76E-09 S006-NB146-69 1.67E+05 1.19E-03 7.15E-09 S006-NB146-139 9.25E+05 2.78E-02 3.01E-08 S006-NB146-150 1.54E+05 6.40E-03 4.16E-08 S006-NB146-173 1.55E+05 4.24E-03 2.74E-08 S006-NB146-181 7.28E+04 1.98E-03 2.72E-08 S006-NB147-220 6.08E+05 1.48E-03 2.43E-09 C33B904 1.01E+06 4.97E-04 4.94E-10

[0256] Example 8: Antibody-antigen binding epitope analysis

[0257] 8.1 Identification of antibody-antigen binding regions

[0258] The CD33 protein has a conserved V-set immunoglobulin-like domain (V-domain) and a variable C2-set domain (C2-domain) extracellularly. The V-domain is located at the distal membrane end, and the C2-domain is located at the proximal membrane end. The antigen-binding epitope of SGN-33 is located in the V-domain, and the antigen-binding epitope of C33B904 is located in the C2-domain. To identify the distribution of antigen-binding epitopes of VHH antibodies, VHH antibodies were classified according to their distal and proximal membrane ends by coating human CD33-V-his (distal membrane end) and human CD33-C2-his (proximal membrane end) respectively, following the ELISA method in Example 5.1. Figure 11A-11D As shown in Table 25, VHH antibodies can be divided into two categories:

[0259] Table 25. Classification of VHH antibodies by distal and proximal epitopes using ELISA method

[0260]

[0261]

[0262] 8.2 Antibody-antigen binding epitope competition assay

[0263] Epitope classification was performed using a competitive ELISA method against control antibodies with known epitopes. Following the method in Example 5.1, 2 μg / mL of antibody was coated onto an ELISA plate. Human CD33-his protein was serially diluted starting at 30 μg / mL, and the EC80 was calculated (Tables 26-27). After coating the ELISA plate with 2 μg / mL of antibody, 25 μg / mL of the antibody to be detected was added, followed by the EC80 concentration of human CD33-his protein corresponding to each antibody. The plate was incubated for 2 h, washed 5 times with PBS, and then HRP-labeled anti-His antibody (purchased from GenScript, catalog number: A00612) was added and incubated for 1 h. The plate was washed 5 times. 50 μL of TMB substrate was added to each well, and the plate was incubated at room temperature for 10 minutes. Then, 50 μL of stop solution (1.0 M HCl) was added to each well. The OD was read using an ELISA reader (Insight, purchased from PerkinElmer). 450nm Numerical value, based on OD 450nm The numerical values ​​were used to calculate the competition rate between antibodies using a formula, and the results are as follows: Figure 12A-12B As shown, the higher the competition rate, the closer the antigenic epitopes of the two antibodies are.

[0264] Table 26. EC80 values ​​of human CD33-his protein corresponding to VHH antibody

[0265] Antibody name EC80 (μg / mL) S006-NB146-1 0.08 S006-NB146-3 0.12 S006-NB146-17 0.09 S006-NB146-20 0.07 S006-NB146-39 0.06 S006-NB146-40 0.10 S006-NB146-46 0.07 S006-NB146-60 0.05 S006-NB146-132 0.06 S006-NB147-225 0.09 C33B904 0.03 SGN-33 0.08

[0266] Table 27. EC80 values ​​of human CD33-his protein corresponding to VHH antibody

[0267] Antibody name EC80 (μg / mL) S006-NB146-16 0.09 S006-NB147-25 0.03

[0268] Antibody name EC80 (μg / mL) S006-NB146-69 1.50 S006-NB146-139 0.02 S006-NB146-150 0.37 S006-NB146-173 0.15 S006-NB146-181 0.25 S006-NB147-220 0.02 C33B904 0.04 SGN-33 0.03

[0269] 8.3 Competition experiment between VHH-Fc antibody and Biotin-C33B904

[0270] Following the method in Example 5.1, 2 μg / mL of human CD33-his protein was coated onto an ELISA plate. Biotin-C33B904 antibody was serially diluted starting at 15 μg / mL, and the EC80 (0.18 μg / mL) was calculated. 2 μg / mL of human CD33-his protein was coated onto the ELISA plate. The VHH antibody to be detected was started at 40 μg / mL and diluted 1:2 to seven concentrations. These concentrations were added to the ELISA plate, followed by the addition of the EC80 concentration of Biotin-C33B904 antibody. The plate was incubated for 2 hours, washed 5 times with PBS, and then incubated for 1 hour with HRP-labeled anti-Streptavidin (Sigma, catalog number: S2438) antibody. The plate was washed 5 times. 50 μL of TMB substrate was added to each well, and the plate was incubated at room temperature for 10 minutes. Then, 50 μL of stop solution (1.0 M HCl) was added to each well. The OD was read using an ELISA plate reader (Insight, PerkinElmer). 450nm The numerical values ​​were then analyzed using software (GraphPad Prism8) to perform data fitting and plot curves. The results are as follows: Figures 13A-13B As shown in Tables 28 and 29.

[0271] Table 28. Competition results between VHH-hFc antibody and Biotin-C33B904

[0272]

[0273] Table 29. Competition results between VHH-hFc antibody and Biotin-C33B904

[0274]

[0275]

[0276] Based on the results of the two competitive methods and the binding experiments with the two truncated proteins, VHH antibodies were classified, and the results are as follows: Figure 14As shown, S006-NB146-1, S006-NB146-39, S006-NB146-46, S006-NB146-132, S006-NB147-25, S006-NB147-220 and C33B904 (combined with table position C2) S006-NB147-225 binds to human CD33-C2-his protein but does not compete with C33B904; S006-NB146-16, S006-NB146-69, S006-NB146-139, S006-NB146-150, S006-NB146-173, and S006-NB146-181 bind to human CD33-C2-his protein and exhibit imperfect competition with C33B904, therefore they are classified as belonging to C2. The domain is not completely identical to the C33B904 epitope; S006-NB146-60 and SGN-33 can both bind to human CD33-V-his protein and are classified as one type; S006-NB146-3, S006-NB146-17, S006-NB146-20, and S006-NB146-40 cannot bind to either human CD33-C2-his protein or human CD33-V-his protein and are classified as one type (spatial conformation).

[0277] Example 9: Humanization of CD33 VHH Single-Domain Antibody

[0278] 9.1 Humanization Design of CD33 VHH Single-Domain Antibody

[0279] By comparing with the IMGT (http: / / imgt.cines.fr) human antibody heavy and light chain variable region germline gene database, the germline genes IGHV3-7*01 and IGHJ3*01, which have high homology with CD33 VHH single-domain antibodies, were selected as templates. The CDRs of CD33 VHH single-domain antibodies S006-NB146-17, S006-NB146-39, S006-NB146-60, S006-NB146-132, S006-NB146-173, and S006-NB147-225 were transplanted into the corresponding human templates, forming a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Key amino acids in the framework region sequence were reverted to the amino acids corresponding to the single-domain antibodies to maintain the original affinity. Point mutations were performed on sites on the antibody that were susceptible to chemical modification (e.g., DD, NSS) to eliminate the risk of modification. Compared to the heavy chain template IGHV3-7*01, the FR3 sequence of the alpaca antibody S006-NB146-39 lacks two amino acids, 77N and 78A. These two newly introduced amino acids (NA) were removed in the humanized S006-NB146-39 antibody. Specific mutation designs are shown in Tables 30-35.

[0280] Table 30. Humanized Antibody Mutation Design for S006-NB146-17

[0281]

[0282]

[0283] Note: S39G indicates that the 39th S is mutated to G, and so on. The amino acid is numbered in natural sequence.

[0284] Table 31. Humanized antibody mutation design for S006-NB146-39

[0285]

[0286] Note: F27I indicates that the 27th F is mutated to I, and so on. del77N indicates that the 77th N is deleted, and del78A indicates that the 78th A is deleted. The amino acid is numbered in natural sequence.

[0287] Table 32. Humanized antibody mutation design for S006-NB146-60

[0288] VHH Name Frame region mutation CDR region mutation CDR area definition method S006-NB146-60-H3 V37H / G44Q / L45R / W47L / N50S / Y58 none IMGT S006-NB146-60-H4 V37H / G44Q / L45R / W47L / N50S / Y58N / I69M / L78V none IMGT S006-NB146-60-H5 V37H / G44Q / L45R / W47L / N50S / Y58N / N73D none IMGT S006-NB146-60-H6 V37H / G44Q / L45R / W47L / N50S / Y58N / N73D / D72N none IMGT S006-NB146-60-H7 V42H / G49Q / L50R / W52L / N55S / Y66N / R95K / A96P none IMGT

[0289] Note: V37H indicates that the 37th V is mutated to H, and so on. The amino acid is numbered in natural sequence.

[0290] Table 33. Humanized antibody mutation design for S006-NB146-132

[0291]

[0292]

[0293] Note: V36Y indicates that the 36th V is mutated to Y, and so on. The amino acid is numbered in natural sequence.

[0294] Table 34. Humanized antibody mutation design for S006-NB146-173

[0295]

[0296] Note: V37Y indicates that the 37th V is mutated to Y, and so on. The amino acid is numbered in natural sequence.

[0297] Table 35. Humanized Antibody Reverse Mutation Design for S006-NB147-225

[0298] VHH Name Reverse mutation CDR region mutation CDR area definition method S006-NB147-225-H5 L4V / R95L / A96P / V101T / W118Q / M123Q none Kabat

[0299] Note: L4V means that the 4th L is mutated to V, and so on. The amino acid is numbered in natural sequence.

[0300] 9.2 Specific sequence of the variable region of the S006-NB146-17 humanized antibody

[0301] S006-NB146-17-H1:

[0302]

[0303] S006-NB146-17-H2:

[0304]

[0305] S006-NB146-17-H3:

[0306]

[0307] S006-NB146-17-H4:

[0308]

[0309] S006-NB146-17-H5:

[0310]

[0311] S006-NB146-17-H6:

[0312]

[0313] S006-NB146-17-H7:

[0314]

[0315] S006-NB146-17-H8:

[0316]

[0317] S006-NB146-17-H9:

[0318]

[0319] 9.3 Specific sequence of the variable region of the S006-NB146-39 humanized antibody

[0320] S006-NB146-39-aH8:

[0321]

[0322] S006-NB146-39-aH9:

[0323]

[0324] S006-NB146-39-aH10:

[0325]

[0326] S006-NB146-39-aH11:

[0327]

[0328] S006-NB146-39-aH12:

[0329]

[0330]

[0331] S006-NB146-39-aH13:

[0332]

[0333] S006-NB146-39-aH15:

[0334]

[0335] 9.4 Specific sequence of the variable region of the S006-NB146-60 humanized antibody

[0336] S006-NB146-60-H3:

[0337]

[0338] S006-NB146-60-H4:

[0339]

[0340] S006-NB146-60-H5:

[0341]

[0342] S006-NB146-60-H6:

[0343]

[0344] S006-NB146-60-H7:

[0345]

[0346] 9.5 Specific sequence of the variable region of the S006-NB146-132 humanized antibody

[0347] S006-NB146-132-aH1:

[0348]

[0349] S006-NB146-132-aH2:

[0350]

[0351] S006-NB146-132-aH3:

[0352]

[0353] S006-NB146-132-aH5:

[0354]

[0355] 9.6 Specific sequence of the variable region of the S006-NB146-173 humanized antibody

[0356] S006-NB146-173-H2:

[0357]

[0358] S006-NB146-173-H3:

[0359]

[0360] S006-NB146-173-H4:

[0361]

[0362] S006-NB146-173-H5:

[0363]

[0364] S006-NB146-173-H6:

[0365]

[0366] 9.7 Specific sequence of the variable region of the S006-NB146-225 humanized antibody

[0367] S006-NB147-225-H5:

[0368]

[0369] 9.8 Humanized template sequence of CD33 VHH single-domain antibody

[0370] Humanized Relink Template IGHV3-7*01:

[0371]

[0372] Humanized heavy link template IGHJ3*01: WGQGTMVTVSS (SEQ ID NO:225).

[0373] 9.9 CDR region sequences of CD33 humanized antibodies (Tables 36-41)

[0374] Table 36. IMGT analysis results of the VHH sequence of the S006-NB146-17 humanized antibody.

[0375]

[0376] Table 37. Kabat analysis results of the VH sequence of the humanized antibody S006-NB146-39

[0377]

[0378] Table 38. IMGT analysis results of the VH sequence of the S006-NB146-60 humanized antibody.

[0379]

[0380] Table 39. Kabat analysis results of the VH sequence of the S006-NB146-132 humanized antibody.

[0381]

[0382] Table 40. Kabat analysis results of the VH sequence of the humanized antibody S006-NB146-173.

[0383]

[0384]

[0385] Table 41. Kabat analysis results of the VH sequence of the S006-NB147-225 humanized antibody.

[0386]

[0387] 9.10 Preparation of CD33 VHH humanized antibody

[0388] The variable region sequence of the aforementioned humanized VHH antibody in this embodiment was recombined into the expression vector BI3.4-huIgG1 containing the signal peptide and human IgG1Fc, and the humanized VHH-Fc antibody was prepared according to the method described in Example 4.1.

[0389] Example 10: Identification of VHH-Fc humanized antibody

[0390] 10.1 Enzyme-linked immunosorbent assay (ELISA) to detect the binding of VHH-Fc humanized antibody to CD33 protein.

[0391] The binding activity of VHH-Fc humanized antibody to human CD33 protein was detected according to the method described in Example 5.1. The ELISA results of VHH humanized antibody and hCD33-his are as follows: Figures 15A-15E As shown, the results indicate that all VHH humanized antibodies can bind to human CD33 protein at the ELISA level.

[0392] 10.2 Flow cytometry (FACS) assay to detect the binding of VHH-Fc humanized antibody to cells expressing different CD33.

[0393] The binding of the VHH-Fc humanized antibody to different CD33-expressing cells was detected according to the method described in Example 5.2. The analysis results are as follows: Figures 16A-16EAs shown in Figures 17A-17E, the VHH humanized antibodies can bind to the human CD33 protein on the surface of CHO-K1-human CD33-B8 cells and U937 cells. Furthermore, the VHH humanized antibodies do not bind to negative Jurkat cells or CHO-K1 empty cells.

[0394] Example 11: Detection of species cross-binding activity of VHH-Fc humanized antibody

[0395] 11.1 ELISA detection of the binding of VHH-Fc humanized antibody to CD33 protein of different species

[0396] ELISA detection was performed according to the method in Example 5.1. The ELISA results for VHH-Fc humanized antibody and mouse CD33 are as follows: Figures 18A-18E As shown, the ELISA results of VHH-Fc humanized antibody and monkey CD33 are as follows: Figure 18F-18J As shown. Except for the humanized antibody S006-NB146-132, other humanized antibodies generally do not bind to mouse CD33, while humanized antibodies except for S006-NB146-60 and S006-NB147-225 all bind to monkey CD33.

[0397] 11.2 FACS detection of the binding of VHH-Fc humanized antibody to monkey CD33 recombinant cell line

[0398] The HEK293T-monkey CD33 cell line was subjected to FACS detection and data analysis according to the method in Example 5.2. The analysis results are as follows: Figures 19A-19E As shown, except for the humanized antibodies S006-NB146-60 and S006-NB147-225, the remaining humanized antibodies all showed binding activity with HEK293T-monkey CD33 cells.

[0399] In addition, tests showed that all humanized antibodies had no binding activity with HEK293T cells used as negative controls.

[0400] Example 12: CD33 antibody affinity assay

[0401] 12.1 Determination of the affinity between VHH-Fc humanized antibody and human CD33-his protein

[0402] The binding rate (Kon), dissociation rate (Koff), and binding affinity (KD) of the VHH-Fc humanized antibody to human CD33-his protein were detected according to the method described in Example 7.1, as shown in Table 15. Only a portion of the humanized antibodies were detected, with antibodies C33B904 and SGN-33 serving as positive controls. As shown in Table 42, the affinity of the detected VHH-Fc humanized antibody to human CD33 was better than 1.61E-07M.

[0403] Table 42. SPR (biacore) assay for the affinity of VHH-Fc antibody to human CD33

[0404] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-17 1.18E+05 2.34E-05 1.98E-10 S006-NB146-17-H1 2.34E+04 3.76E-03 1.61E-07 S006-NB146-17-H2 4.87E+04 1.03E-04 2.11E-09 S006-NB146-17-H3 7.30E+04 9.69E-05 1.33E-09 S006-NB146-17-H4 7.83E+04 6.68E-05 8.53E-10 S006-NB146-17-H5 7.73E+04 7.11E-05 9.20E-10 S006-NB146-17-H6 7.49E+04 4.47E-05 5.98E-10 S006-NB146-17-H7 7.16E+04 7.60E-05 1.06E-09 S006-NB146-17-H8 7.17E+04 7.69E-05 1.07E-09 S006-NB146-17-H9 7.32E+04 8.86E-05 1.21E-09 S006-NB146-60 1.25E+05 1.47E-04 1.18E-09 S006-NB146-60-H3 1.86E+04 5.07E-04 2.72E-08 S006-NB146-60-H4 4.32E+04 1.51E-04 3.49E-09 S006-NB146-60-H5 1.48E+04 8.17E-04 5.53E-08 S006-NB146-60-H6 1.17E+04 8.15E-04 6.98E-08 S006-NB146-60-H7 1.85E+04 4.25E-04 2.29E-08 S006-NB147-225 8.19E+04 2.33E-04 2.84E-09 S006-NB147-225-H5 3.59E+04 4.98E-04 1.39E-08 S006-NB146-132 1.31E+05 6.96E-05 5.31E-10 S006-NB146-132-aH1 3.17E+05 1.42E-03 4.50E-09 S006-NB146-132-aH2 5.37E+05 2.80E-04 5.21E-10 S006-NB146-132-aH3 4.77E+05 2.94E-04 6.17E-10 S006-NB146-132-aH5 6.88E+05 2.34E-04 3.41E-10 S006-NB146-39-aH8 2.04E+05 9.00E-04 4.42E-09 S006-NB146-39-aH9 2.55E+05 1.34E-03 5.25E-09 S006-NB146-39-aH10 1.99E+05 7.85E-05 3.95E-10 S006-NB146-39-aH11 2.80E+05 1.51E-04 5.38E-10 S006-NB146-39-aH12 2.08E+05 1.50E-03 7.21E-09 S006-NB146-39-aH13 2.31E+05 1.95E-03 8.43E-09 S006-NB146-39-aH15 1.58E+05 9.10E-04 5.77E-09 S006-NB146-173 1.85E+05 1.79E-03 9.68E-09

[0405] S006-NB146-173-H5 9.99E+04 6.11E-03 6.12E-08 S006-NB146-173-H6 2.14E+05 1.63E-03 7.60E-09 C33B904 8.28E+05 6.54E-05 7.90E-11 SGN-33 7.02E+05 5.57E-03 7.93E-09

[0406] 12.2 Affinity determination of VHH-Fc with monkey CD33-his protein

[0407] The affinity of VHH-Fc antibody to monkey CD33 (Sino Biological, catalog number: 50712-M08H) protein was determined according to the method in Example 7.2. As shown in Table 43, the affinity of VHH-Fc humanized antibody to monkey CD33 was better than that of 1.0E-07M.

[0408] Table 43. SPR (biacore) assay for affinity between VHH-Fc antibody and monkey CD33

[0409] Antibody name Kon(1 / Ms) Koff(1 / s) KD(M) S006-NB146-39-aH8 3.71E+05 1.77E-02 4.78E-08 S006-NB146-39-aH9 4.34E+05 1.85E-02 4.26E-08 S006-NB146-39-aH10 3.65E+05 8.29E-04 2.27E-09 S006-NB146-39-aH11 5.34E+05 1.45E-03 2.72E-09 S006-NB146-39-aH12 3.77E+05 2.65E-02 7.02E-08 S006-NB146-39-aH13 3.83E+05 2.35E-02 6.14E-08 S006-NB146-39-aH15 3.08E+05 1.71E-02 5.57E-08 S006-NB146-173-H5 1.52E+05 1.44E-02 9.51E-08 S006-NB146-173-H6 3.23E+05 5.20E-03 1.61E-08 C33B904 1.11E+06 6.26E-04 5.65E-10

[0410] Example 13: Identification of antibody-antigen binding regions

[0411] Following the ELISA method in Example 8, human CD33-V-his (distal membrane end) and human CD33-C2-his (proximal membrane end) were coated respectively to classify the VHH humanized antibody by distal and proximal membrane ends, as follows: Figure 20A-20J As shown in Table 44, VHH humanized antibodies can be classified into the following categories.

[0412] The humanized antibody of molecule S006-NB146-17 cannot bind to either human CD33-C2-his or human CD33-V-his protein, and its spatial conformation is consistent with the parent clone's epitope. The humanized antibody of molecule S006-NB146-60 can bind to human CD33-V-his protein, and its binding epitope belongs to the V domain. The humanized antibody of molecule S006-NB147-225 can bind to human CD33-C2-his protein, and its binding epitope belongs to the C2 domain. Of the humanized antibodies of molecule S006-NB146-39, only S006-NB146-39-aH10 and S006-NB146-39-aH11 can bind to human CD33-C2-his protein, and their binding epitopes belong to the C2 domain. The humanized antibody of molecule S006-NB146-173, except for S006-NB146-173-H2, is identical to the parent clone and belongs to the C2 domain; the humanized antibody of molecule S006-NB146-132 can bind to human CD33-C2-his protein, and the binding epitope belongs to the C2 domain.

[0413] Table 44. Classification of VHH antibodies by distal and proximal epitopes using ELISA method

[0414]

[0415] sequence list <110> Simcere Pharmaceutical Co., Ltd. <120> Human CD33 antibodies and their uses <150> 202280013967.6 <151> 2022-02-09 <160> 230 <170> SIPOSequenceListing 1.0 <210> 1 <211> 471 <212> PRT <213> Artificial Sequence <400> 1 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Ala Lys Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Gly Tyr Glu Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 130 135 140 Ala Ser Val Gly Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asp 145 150 155 160 Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro 165 170 175 Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser 180 185 190 Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Thr Leu Thr Ile Ser 195 200 205 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp 210 215 220 Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Glu 225 230 235 240 Pro Lys Ser Ala Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys 465 470 <210> 2 <211> 449 <212> PRT <213> Artificial Sequence <400> 2 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Gly Trp Ser Gly Gly Ser Ile Val Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Asp Ser Pro Tyr Gly Asp Phe Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340 345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys <210> 3 <211> 220 <212> PRT <213> Artificial Sequence <400> 3 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Thr Val Phe Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Lys Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Val Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His 85 90 95 Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 220 <210> 4 <211> 129 <212> PRT <213> Artificial Sequence <400> 4 Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln Glu 1 5 10 15 Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro Tyr 20 25 30 Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly Ala 35 40 45 Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln Glu 50 55 60 Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro Ser 65 70 75 80 Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp Asn 85 90 95 Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser Tyr 100 105 110 Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg Gly 115 120 125 Ser <210> 5 <211> 126 <212> PRT <213> Artificial Sequence <400> 5 Val His Val Thr Asp Leu Thr His Arg Pro Lys Ile Leu Ile Pro Gly 1 5 10 15 Thr Leu Glu Pro Gly His Ser Lys Asn Leu Thr Cys Ser Val Ser Trp 20 25 30 Ala Cys Glu Gln Gly Thr Pro Pro Ile Phe Ser Trp Leu Ser Ala Ala 35 40 45 Pro Thr Ser Leu Gly Pro Arg Thr Thr His Ser Ser Val Leu Ile Ile 50 55 60 Thr Pro Arg Pro Gln Asp His Gly Thr Asn Leu Thr Cys Gln Val Lys 65 70 75 80 Phe Ala Gly Ala Gly Val Thr Thr Glu Arg Thr Ile Gln Leu Asn Val 85 90 95 Thr Tyr Val Pro Gln Asn Pro Thr Thr Gly Ile Phe Pro Gly Asp Gly 100 105 110 Ser Gly Lys Gln Glu Thr Arg Ala Gly Val Val His Gly Ser 115 120 125 <210> 6 <211> 18 <212> DNA / RNA <213> Artificial Sequence <400> 6 Cys Thr Thr Gly Gly Thr Gly Gly Thr Cys Cys Thr Gly Gly Cys Thr 1 5 10 15 Gly Cys <210> 7 <211> 23 <212> DNA / RNA <213> Artificial Sequence <400> 7 Gly Gly Thr Ala Cys Gly Thr Gly Cys Thr Gly Thr Thr Gly Ala Ala 1 5 10 15 Cys Thr Gly Thr Thr Cys Cys 20 <210> 8 <211> 47 <212> DNA / RNA <213> Artificial Sequence <400> 8 Cys Ala Thr Gly Cys Cys Ala Thr Gly Ala Cys Thr Gly Thr Gly Gly 1 5 10 15 Cys Cys Cys Ala Gly Gly Cys Gly Gly Cys Cys Cys Ala Gly Lys Thr 20 25 30 Gly Cys Ala Gly Cys Thr Cys Gly Thr Gly Gly Ala Gly Thr Cys 35 40 45 <210> 9 <211> 51 <212> DNA / RNA <213> Artificial Sequence <400> 9 Cys Ala Thr Gly Cys Cys Ala Thr Gly Ala Cys Thr Cys Gly Cys Gly 1 5 10 15 Gly Cys Cys Gly Gly Cys Cys Thr Gly Gly Cys Cys Ala Thr Gly Gly 20 25 30 Gly Gly Gly Thr Cys Thr Thr Cys Gly Cys Thr Gly Thr Gly Gly Thr 35 40 45 Gly Cys Gly 50 <210> 10 <211> 52 <212> DNA / RNA <213> Artificial Sequence <400> 10 Cys Ala Thr Gly Cys Cys Ala Thr Gly Ala Cys Thr Cys Gly Cys Gly 1 5 10 15 Gly Cys Cys Gly Gly Cys Cys Thr Gly Gly Cys Cys Gly Thr Cys Thr 20 25 30 Thr Gly Thr Gly Gly Thr Thr Thr Thr Gly Gly Thr Gly Thr Cys Thr 35 40 45 Thr Gly Gly Gly 50 <210> 11 <211> 119 <212> PRT <213> Artificial Sequence <400> 11 Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Asn Ile Glu Asn Ile Gln 20 25 30 Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Ser Gln Arg Ala Leu Val 35 40 45 Ala Gln Ile Asn Leu Ser Gly Leu Glu Ser Thr Asn Tyr Leu Asp Ser 50 55 60 Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Tyr Thr Lys Asn Ala Val 65 70 75 80 Tyr Leu Arg Met Asn Arg Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Asn Ala Arg Ser Tyr Tyr Gly Gln Tyr Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Gln Val Thr Val Ser Ser 115 <210> 12 <211> 125 <212> PRT <213> Artificial Sequence <400> 12 Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Ile Phe Thr Ser Asn 20 25 30 Ala Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Val Ser Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Asp Asp Thr Asn Tyr Gly 50 55 60 Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn 65 70 75 80 Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Thr Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 13 <211> 125 <212> PRT <213> Artificial Sequence <400> 13 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Ser Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Gly 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn 65 70 75 80 Thr Ala Phe Leu Gln Met Asn Thr Leu Lys Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 14 <211> 113 <212> PRT <213> Artificial Sequence <400> 14 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Gly Thr Pro Gln Ser Trp Phe Arg Leu Ser 20 25 30 Ser Tyr Val Met Asn Trp Tyr Arg Gln Ala Pro Gly Lys Arg Arg Glu 35 40 45 Leu Val Ala Glu Ile Thr Gln Asp Asp Thr Thr Asn Tyr Thr Pro Ser 50 55 60 Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Asn Asn Thr Val 65 70 75 80 His Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Asn Thr Ile Gln Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser 100 105 110 Ser <210> 15 <211> 130 <212> PRT <213> Artificial Sequence <400> 15 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Pro Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Lys Asn Thr Val 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ser Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 115 120 125 Ser Ser 130 <210> 16 <211> 125 <212> PRT <213> Artificial Sequence <400> 16 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asn 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Val Ser Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Gly 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn 65 70 75 80 Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Leu Arg Ser Asp Arg Ser Thr Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 17 <211> 130 <212> PRT <213> Artificial Sequence <400> 17 Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Pro Gly Ile Val Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ser Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Lys Asn Thr Val 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ala Ser Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 115 120 125 Ser Ser 130 <210> 18 <211> 121 <212> PRT <213> Artificial Sequence <400> 18 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Glu Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Asp Arg Phe Ile Met Thr Arg Asp Asp Ala Lys Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 19 <211> 120 <212> PRT <213> Artificial Sequence <400> 19 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Val Ile Asn 20 25 30 Ala Ala Trp Tyr His Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 35 40 45 Asn Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 50 55 60 Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln 65 70 75 80 Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Arg Leu 85 90 95 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr Trp Gly Gln 100 105 110 Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 20 <211> 118 <212> PRT <213> Artificial Sequence <400> 20 Glu Val Gln Val Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Lys Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Asn Ser Gly Gly Asp Asn Thr Tyr Tyr Ala Tyr Phe Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Glu Glu Asn Ala Gly Thr Ile Leu Gln Gly Gln Gly Thr 100 105 110 Gln Val Thr Val Ser Ser 115 <210> 21 <211> 119 <212> PRT <213> Artificial Sequence <400> 21 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Pro Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Ala Asn Ile Gln 20 25 30 Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Ser Gln Arg Ala Leu Val 35 40 45 Ala Gln Ile Thr Val Thr Gly Asp Arg Ala Thr Asn Tyr Ala Asp Ser 50 55 60 Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ala Val 65 70 75 80 Tyr Leu Ser Ile Asn Pro Leu Lys Ser Glu Asp Thr Gly Val Tyr Tyr 85 90 95 Cys Asn Ala Arg Ser Tyr Tyr Gly Gln His Asn Tyr Trp Gly Gln Gly 100 105 110 Thr Gln Val Thr Val Ser Ser 115 <210> 22 <211> 121 <212> PRT <213> Artificial Sequence <400> 22 Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Lys Ala Ser Gly Val Thr Phe Ser Ile Asn 20 25 30 Ala Leu Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Met Val 35 40 45 Ala Val Ile Ser Ser Gly Gly Ser Thr Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Asp Val Val Gly Ser Ser Trp Ser Pro Glu Tyr Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Thr 115 120 <210> 23 <211> 121 <212> PRT <213> Artificial Sequence <400> 23 Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ile Asn 20 25 30 Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gln Ile Asn Arg Val Gly Asp Thr Asn Tyr Pro Asn Ser Met Ala 50 55 60 Glu Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu 65 70 75 80 Gln Met Asn Thr Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Asp Ile Val Glu Ser Gly Arg Tyr Ser Gly Lys Asp Tyr Trp Gly 100 105 110 Lys Gly Thr Leu Val Thr Val Ser Leu 115 120 <210> 24 <211> 130 <212> PRT <213> Artificial Sequence <400> 24 Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Pro Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ser Tyr Ile Thr Ser Ser Asp Asp Ser Thr Val Tyr Thr Tyr Tyr Thr 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Gly Lys Asn Thr Val 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Tyr His Thr Leu 100 105 110 Asn Ser Ser Asp Phe Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 115 120 125 Ser Ser 130 <210> 25 <211> 121 <212> PRT <213> Artificial Sequence <400> 25 Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Leu Gly Val Tyr 20 25 30 Asn Leu Gly Trp Tyr Arg Gln Ala Pro Gly Glu Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Asn Ser Arg Gly Asp Thr Asn Tyr Val Asn Ser Val Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Val Asn Ala Arg Asn Thr Glu Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Arg Leu Gln Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ile Ala Gln Arg Gly Trp Gly Arg Glu Tyr Asp Ile Trp Gly 100 105 110 Pro Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 26 <211> 117 <212> PRT <213> Artificial Sequence <400> 26 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Leu Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Ala Gly Arg Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Phe Ile Ser Arg Asp Gly Thr Lys Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Thr Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 27 <211> 115 <212> PRT <213> Artificial Sequence <400> 27 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Met Gly 20 25 30 Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Ala Ile 35 40 45 Ala Asn Gly Gly Thr Thr Thr Asn Tyr Ala Asn Ser Val Lys Asp Arg 50 55 60 Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met 65 70 75 80 Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr Ala Lys 85 90 95 Arg Ser Trp Asp Ser Ser Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115 <210> 28 <211> 128 <212> PRT <213> Artificial Sequence <400> 28 Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Met Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Tyr Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ser Cys Ile Asn Ser Gly Asp Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Val Asp Thr Leu Ile Val Ala Gly Asn Leu Glu Glu Cys Arg 100 105 110 Tyr Asp Met Asp Tyr Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 29 <211> 5 <212> PRT <213> Artificial Sequence <400> 29 Ile Gln Val Met Gly 1 5 <210> 30 <211> 18 <212> PRT <213> Artificial Sequence <400> 30 Gln Ile Asn Leu Ser Gly Leu Glu Ser Thr Asn Tyr Leu Asp Ser Val 1 5 10 15 Lys Glu <210> 31 <211> 9 <212> PRT <213> Artificial Sequence <400> 31 Arg Ser Tyr Tyr Gly Gln Tyr Asp Tyr 1 5 <210> 32 <211> 9 <212> PRT <213> Artificial Sequence <400> 32 Ser Asn Ala Met Asp Tyr Ala Met Gly 1 5 <210> 33 <211> 16 <212> PRT <213> Artificial Sequence <400> 33 Thr Ile Thr Ser Asp Asp Asp Thr Asn Tyr Gly Asp Ser Ala Lys Gly 1 5 10 15 <210> 34 <211> 13 <212> PRT <213> Artificial Sequence <400> 34 Asn Val Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 <210> 35 <211> 9 <212> PRT <213> Artificial Sequence <400> 35 Ser Asp Asp Met Asp Tyr Ala Met Gly 1 5 <210> 36 <211> 16 <212> PRT <213> Artificial Sequence <400> 36 Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Gly Asp Ser Val Lys Gly 1 5 10 15 <210> 37 <211> 13 <212> PRT <213> Artificial Sequence <400> 37 Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg Asn Tyr 1 5 10 <210> 38 <211> 7 <212> PRT <213> Artificial Sequence <400> 38 Leu Ser Ser Tyr Val Met Asn 1 5 <210> 39 <211> 16 <212> PRT <213> Artificial Sequence <400> 39 Glu Ile Thr Gln Asp Asp Thr Thr Asn Tyr Thr Pro Ser Val Lys Gly 1 5 10 15 <210> 40 <211> 3 <212> PRT <213> Artificial Sequence <400> 40 Ile Gln Ile 1 <210> 41 <211> 5 <212> PRT <213> Artificial Sequence <400> 41 Tyr Tyr Pro Ile Gly 1 5 <210> 42 <211> 20 <212> PRT <213> Artificial Sequence <400> 42 Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala Asp 1 5 10 15 Ser Val Lys Gly 20 <210> 43 <211> 20 <212> PRT <213> Artificial Sequence <400> 43 Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn Ser Ser 1 5 10 15 Asp Tyr Asp Tyr 20 <210> 44 <211> 9 <212> PRT <213> Artificial Sequence <400> 44 Ser Asn Asp Met Asp Tyr Ala Met Gly 1 5 <210> 45 <211> 16 <212> PRT <213> Artificial Sequence <400> 45 Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Gly Asp Ser Val Lys Gly 1 5 10 15 <210> 46 <211> 13 <212> PRT <213> Artificial Sequence <400> 46 Asn Leu Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 <210> 47 <211> 5 <212> PRT <213> Artificial Sequence <400> 47 Tyr Tyr Pro Ile Gly 1 5 <210> 48 <211> 20 <212> PRT <213> Artificial Sequence <400> 48 Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala Asp 1 5 10 15 Ser Val Lys Gly 20 <210> 49 <211> 20 <212> PRT <213> Artificial Sequence <400> 49 Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn Ala Ser 1 5 10 15 Asp Tyr Asp Tyr 20 <210> 50 <211> 5 <212> PRT <213> Artificial Sequence <400> 50 Leu Ser Leu Met Ser 1 5 <210> 51 <211> 16 <212> PRT <213> Artificial Sequence <400> 51 Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys Asp 1 5 10 15 <210> 52 <211> 13 <212> PRT <213> Artificial Sequence <400> 52 Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala 1 5 10 <210> 53 <211> 4 <212> PRT <213> Artificial Sequence <400> 53 Ile Asn Ala Ala 1 <210> 54 <211> 16 <212> PRT <213> Artificial Sequence <400> 54 Asn Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 1 5 10 15 <210> 55 <211> 13 <212> PRT <213> Artificial Sequence <400> 55 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr 1 5 10 <210> 56 <211> 5 <212> PRT <213> Artificial Sequence <400> 56 Asn Tyr Ala Met Ser 1 5 <210> 57 <211> 17 <212> PRT <213> Artificial Sequence <400> 57 Glu Ile Asn Ser Gly Gly Asp Asn Thr Tyr Tyr Tyr Ala Tyr Phe Val Lys 1 5 10 15 Gly <210> 58 <211> 9 <212> PRT <213> Artificial Sequence <400> 58 Glu Glu Glu Asn Ala Gly Thr Ile Leu 1 5 <210> 59 <211> 5 <212> PRT <213> Artificial Sequence <400> 59 Ile Gln Val Met Gly 1 5 <210> 60 <211> 18 <212> PRT <213> Artificial Sequence <400> 60 Gln Ile Thr Val Thr Gly Asp Arg Ala Thr Asn Tyr Ala Asp Ser Val 1 5 10 15 Lys Gly <210> 61 <211> 9 <212> PRT <213> Artificial Sequence <400> 61 Arg Ser Tyr Tyr Gly Gln His Asn Tyr 1 5 <210> 62 <211> 5 <212> PRT <213> Artificial Sequence <400> 62 Ile Asn Ala Leu Gly 1 5 <210> 63 <211> 16 <212> PRT <213> Artificial Sequence <400> 63 Val Ile Ser Ser Gly Gly Ser Thr Asn Tyr Val Asp Ser Val Lys Gly 1 5 10 15 <210> 64 <211> 13 <212> PRT <213> Artificial Sequence <400> 64 Asp Val Val Gly Ser Ser Trp Ser Pro Glu Tyr Asp Tyr 1 5 10 <210> 65 <211> 5 <212> PRT <213> Artificial Sequence <400> 65 Ile Asn Ile Met Gly 1 5 <210> 66 <211> 16 <212> PRT <213> Artificial Sequence <400> 66 Gln Ile Asn Arg Val Gly Asp Thr Asn Tyr Pro Asn Ser Met Ala Glu 1 5 10 15 <210> 67 <211> 13 <212> PRT <213> Artificial Sequence <400> 67 Asp Ile Val Glu Ser Gly Arg Tyr Ser Gly Lys Asp Tyr 1 5 10 <210> 68 <211> 5 <212> PRT <213> Artificial Sequence <400> 68 Tyr Tyr Pro Ile Gly 1 5 <210> 69 <211> 20 <212> PRT <213> Artificial Sequence <400> 69 Tyr Ile Thr Ser Ser Asp Asp Ser Thr Val Tyr Thr Tyr Tyr Thr Asp 1 5 10 15 Ser Val Lys Gly 20 <210> 70 <211> 20 <212> PRT <213> Artificial Sequence <400> 70 Arg Ser Thr Tyr Ile Val Gly Arg Asn Tyr His Thr Leu Asn Ser Ser 1 5 10 15 Asp Phe Asp Tyr 20 <210> 71 <211> 5 <212> PRT <213> Artificial Sequence <400> 71 Val Tyr Asn Leu Gly 1 5 <210> 72 <211> 16 <212> PRT <213> Artificial Sequence <400> 72 Thr Ile Asn Ser Arg Gly Asp Thr Asn Tyr Val Asn Ser Val Ala Gly 1 5 10 15 <210> 73 <211> 10 <212> PRT <213> Artificial Sequence <400> 73 Gln Arg Gly Trp Gly Arg Glu Tyr Asp Ile 1 5 10 <210> 74 <211> 5 <212> PRT <213> Artificial Sequence <400> 74 Leu His Ser Met Gly 1 5 <210> 75 <211> 16 <212> PRT <213> Artificial Sequence <400> 75 Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala Gly 1 5 10 15 <210> 76 <211> 9 <212> PRT <213> Artificial Sequence <400> 76 Arg Thr Ser Pro Trp Ser Ala Ala Leu 1 5 <210> 77 <211> 2 <212> PRT <213> Artificial Sequence <400> 77 Met Gly 1 <210> 78 <211> 17 <212> PRT <213> Artificial Sequence <400> 78 Ala Ile Ala Asn Gly Gly Thr Thr Thr Asn Tyr Ala Asn Ser Val Lys 1 5 10 15 Asp <210> 79 <211> 9 <212> PRT <213> Artificial Sequence <400> 79 Lys Arg Ser Trp Asp Ser Ser Ser Tyr 1 5 <210> 80 <211> 5 <212> PRT <213> Artificial Sequence <400> 80 Tyr Tyr Ala Ile Gly 1 5 <210> 81 <211> 17 <212> PRT <213> Artificial Sequence <400> 81 Cys Ile Asn Ser Gly Asp Ser Ser Thr Tyr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 82 <211> 19 <212> PRT <213> Artificial Sequence <400> 82 Val Asp Thr Leu Ile Val Ala Gly Asn Leu Glu Glu Cys Arg Tyr Asp 1 5 10 15 Met Asp Tyr <210> 83 <211> 7 <212> PRT <213> Artificial Sequence <400> 83 Gly Asn Ile Glu Asn Ile Gln 1 5 <210> 84 <211> 7 <212> PRT <213> Artificial Sequence <400> 84 Asn Leu Ser Gly Leu Glu Ser 1 5 <210> 85 <211> 9 <212> PRT <213> Artificial Sequence <400> 85 Arg Ser Tyr Tyr Gly Gln Tyr Asp Tyr 1 5 <210> 86 <211> 11 <212> PRT <213> Artificial Sequence <400> 86 Gly Ala Ile Phe Thr Ser Asn Ala Met Asp Tyr 1 5 10 <210> 87 <211> 5 <212> PRT <213> Artificial Sequence <400> 87 Thr Ser Asp Asp Asp 1 5 <210> 88 <211> 13 <212> PRT <213> Artificial Sequence <400> 88 Asn Val Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 <210> 89 <211> 11 <212> PRT <213> Artificial Sequence <400> 89 Gly Ser Ile Phe Thr Ser Asp Asp Met Asp Tyr 1 5 10 <210> 90 <211> 5 <212> PRT <213> Artificial Sequence <400> 90 Thr Ser Asp Glu Asp 1 5 <210> 91 <211> 13 <212> PRT <213> Artificial Sequence <400> 91 Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg Asn Tyr 1 5 10 <210> 92 <211> 9 <212> PRT <213> Artificial Sequence <400> 92 Gln Ser Trp Phe Arg Leu Ser Ser Tyr 1 5 <210> 93 <211> 5 <212> PRT <213> Artificial Sequence <400> 93 Thr Gln Asp Asp Thr 1 5 <210> 94 <211> 3 <212> PRT <213> Artificial Sequence <400> 94 Ile Gln Ile 1 <210> 95 <211> 7 <212> PRT <213> Artificial Sequence <400> 95 Gly Ile Ile Leu Asp Tyr Tyr 1 5 <210> 96 <211> 9 <212> PRT <213> Artificial Sequence <400> 96 Thr Asn Ser Asp Asp Ser Thr Ile Tyr 1 5 <210> 97 <211> 20 <212> PRT <213> Artificial Sequence <400> 97 Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn Ser Ser 1 5 10 15 Asp Tyr Asp Tyr 20 <210> 98 <211> 11 <212> PRT <213> Artificial Sequence <400> 98 Gly Ser Ile Phe Thr Ser Asn Asp Met Asp Tyr 1 5 10 <210> 99 <211> 5 <212> PRT <213> Artificial Sequence <400> 99 Thr Ser Asp Glu Asp 1 5 <210> 100 <211> 13 <212> PRT <213> Artificial Sequence <400> 100 Asn Leu Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 <210> 101 <211> 7 <212> PRT <213> Artificial Sequence <400> 101 Gly Ile Val Leu Asp Tyr Tyr 1 5 <210> 102 <211> 9 <212> PRT <213> Artificial Sequence <400> 102 Thr Asn Ser Asp Asp Ser Thr Ile Tyr 1 5 <210> 103 <211> 20 <212> PRT <213> Artificial Sequence <400> 103 Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn Ala Ser 1 5 10 15 Asp Tyr Asp Tyr 20 <210> 104 <211> 7 <212> PRT <213> Artificial Sequence <400> 104 Arg Ser Thr Ser Ser Leu Ser 1 5 <210> 105 <211> 5 <212> PRT <213> Artificial Sequence <400> 105 Thr Ser Gly Gly Lys 1 5 <210> 106 <211> 13 <212> PRT <213> Artificial Sequence <400> 106 Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala 1 5 10 <210> 107 <211> 6 <212> PRT <213> Artificial Sequence <400> 107 Gly Gly Thr Phe Val Ile 1 5 <210> 108 <211> 5 <212> PRT <213> Artificial Sequence <400> 108 Ser Tyr Gly Gly Ser 1 5 <210> 109 <211> 13 <212> PRT <213> Artificial Sequence <400> 109 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr 1 5 10 <210> 110 <211> 7 <212> PRT <213> Artificial Sequence <400> 110 Gly Phe Thr Phe Ser Asn Tyr 1 5 <210> 111 <211> 6 <212> PRT <213> Artificial Sequence <400> 111 Asn Ser Gly Gly Asp Asn 1 5 <210> 112 <211> 9 <212> PRT <213> Artificial Sequence <400> 112 Glu Glu Glu Asn Ala Gly Thr Ile Leu 1 5 <210> 113 <211> 7 <212> PRT <213> Artificial Sequence <400> 113 Gly Ser Ile Ala Asn Ile Gln 1 5 <210> 114 <211> 7 <212> PRT <213> Artificial Sequence <400> 114 Thr Val Thr Gly Asp Arg Ala 1 5 <210> 115 <211> 9 <212> PRT <213> Artificial Sequence <400> 115 Arg Ser Tyr Tyr Gly Gln His Asn Tyr 1 5 <210> 116 <211> 7 <212> PRT <213> Artificial Sequence <400> 116 Gly Val Thr Phe Ser Ile Asn 1 5 <210> 117 <211> 5 <212> PRT <213> Artificial Sequence <400> 117 Ser Ser Gly Gly Ser 1 5 <210> 118 <211> 13 <212> PRT <213> Artificial Sequence <400> 118 Asp Val Val Gly Ser Ser Trp Ser Pro Glu Tyr Asp Tyr 1 5 10 <210> 119 <211> 7 <212> PRT <213> Artificial Sequence <400> 119 Gly Ser Ile Phe Thr Ile Asn 1 5 <210> 120 <211> 5 <212> PRT <213> Artificial Sequence <400> 120 Asn Arg Val Gly Asp 1 5 <210> 121 <211> 13 <212> PRT <213> Artificial Sequence <400> 121 Asp Ile Val Glu Ser Gly Arg Tyr Ser Gly Lys Asp Tyr 1 5 10 <210> 122 <211> 7 <212> PRT <213> Artificial Sequence <400> 122 Gly Ile Ile Leu Asp Tyr Tyr 1 5 <210> 123 <211> 9 <212> PRT <213> Artificial Sequence <400> 123 Thr Ser Ser Asp Asp Ser Thr Val Tyr 1 5 <210> 124 <211> 20 <212> PRT <213> Artificial Sequence <400> 124 Arg Ser Thr Tyr Ile Val Gly Arg Asn Tyr His Thr Leu Asn Ser Ser 1 5 10 15 Asp Phe Asp Tyr 20 <210> 125 <211> 7 <212> PRT <213> Artificial Sequence <400> 125 Gly Asn Ser Leu Gly Val Tyr 1 5 <210> 126 <211> 5 <212> PRT <213> Artificial Sequence <400> 126 Asn Ser Arg Gly Asp 1 5 <210> 127 <211> 10 <212> PRT <213> Artificial Sequence <400> 127 Gln Arg Gly Trp Gly Arg Glu Tyr Asp Ile 1 5 10 <210> 128 <211> 7 <212> PRT <213> Artificial Sequence <400> 128 Gly Ser Thr Leu Ser Leu His 1 5 <210> 129 <211> 5 <212> PRT <213> Artificial Sequence <400> 129 Ser Arg Asp Gly Asp 1 5 <210> 130 <211> 9 <212> PRT <213> Artificial Sequence <400> 130 Arg Thr Ser Pro Trp Ser Ala Ala Leu 1 5 <210> 131 <211> 4 <212> PRT <213> Artificial Sequence <400> 131 Gly Ser Ile Phe 1 <210> 132 <211> 6 <212> PRT <213> Artificial Sequence <400> 132 Ala Asn Gly Gly Thr Thr 1 5 <210> 133 <211> 9 <212> PRT <213> Artificial Sequence <400> 133 Lys Arg Ser Trp Asp Ser Ser Ser Tyr 1 5 <210> 134 <211> 7 <212> PRT <213> Artificial Sequence <400> 134 Gly Phe Thr Leu Asp Tyr Tyr 1 5 <210> 135 <211> 6 <212> PRT <213> Artificial Sequence <400> 135 Asn Ser Gly Asp Ser Ser 1 5 <210> 136 <211> 19 <212> PRT <213> Artificial Sequence <400> 136 Val Asp Thr Leu Ile Val Ala Gly Asn Leu Glu Glu Cys Arg Tyr Asp 1 5 10 15 Met Asp Tyr <210> 137 <211> 8 <212> PRT <213> Artificial Sequence <400> 137 Gly Asn Ile Glu Asn Ile Gln Val 1 5 <210> 138 <211> 9 <212> PRT <213> Artificial Sequence <400> 138 Ile Asn Leu Ser Gly Leu Glu Ser Thr 1 5 <210> 139 <211> 11 <212> PRT <213> Artificial Sequence <400> 139 Asn Ala Arg Ser Tyr Tyr Gly Gln Tyr Asp Tyr 1 5 10 <210> 140 <211> 12 <212> PRT <213> Artificial Sequence <400> 140 Gly Ala Ile Phe Thr Ser Asn Ala Met Asp Tyr Ala 1 5 10 <210> 141 <211> 7 <212> PRT <213> Artificial Sequence <400> 141 Ile Thr Ser Asp Asp Asp Thr 1 5 <210> 142 <211> 15 <212> PRT <213> Artificial Sequence <400> 142 Phe Ala Asn Val Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 15 <210> 143 <211> 12 <212> PRT <213> Artificial Sequence <400> 143 Gly Ser Ile Phe Thr Ser Asp Asp Met Asp Tyr Ala 1 5 10 <210> 144 <211> 7 <212> PRT <213> Artificial Sequence <400> 144 Ile Thr Ser Asp Glu Asp Thr 1 5 <210> 145 <211> 15 <212> PRT <213> Artificial Sequence <400> 145 Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg Asn Tyr 1 5 10 15 <210> 146 <211> 10 <212> PRT <213> Artificial Sequence <400> 146 Gln Ser Trp Phe Arg Leu Ser Ser Tyr Val 1 5 10 <210> 147 <211> 7 <212> PRT <213> Artificial Sequence <400> 147 Ile Thr Gln Asp Asp Thr Thr 1 5 <210> 148 <211> 5 <212> PRT <213> Artificial Sequence <400> 148 Asn Thr Ile Gln Ile 1 5 <210> 149 <211> 8 <212> PRT <213> Artificial Sequence <400> 149 Gly Ile Ile Leu Asp Tyr Tyr Pro 1 5 <210> 150 <211> 11 <212> PRT <213> Artificial Sequence <400> 150 Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr 1 5 10 <210> 151 <211> twenty two <212> PRT <213> Artificial Sequence <400> 151 Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn 1 5 10 15 Ser Ser Asp Tyr Asp Tyr 20 <210> 152 <211> 12 <212> PRT <213> Artificial Sequence <400> 152 Gly Ser Ile Phe Thr Ser Asn Asp Met Asp Tyr Ala 1 5 10 <210> 153 <211> 7 <212> PRT <213> Artificial Sequence <400> 153 Ile Thr Ser Asp Glu Asp Thr 1 5 <210> 154 <211> 15 <212> PRT <213> Artificial Sequence <400> 154 Phe Ala Asn Leu Arg Ser Asp Arg Ser Thr Leu Tyr Arg Asn Tyr 1 5 10 15 <210> 155 <211> 8 <212> PRT <213> Artificial Sequence <400> 155 Gly Ile Val Leu Asp Tyr Tyr Pro 1 5 <210> 156 <211> 11 <212> PRT <213> Artificial Sequence <400> 156 Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr 1 5 10 <210> 157 <211> twenty two <212> PRT <213> Artificial Sequence <400> 157 Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn 1 5 10 15 Ala Ser Asp Tyr Asp Tyr 20 <210> 158 <211> 8 <212> PRT <213> Artificial Sequence <400> 158 Arg Ser Thr Ser Ser Ser Leu Ser Leu 1 5 <210> 159 <211> 7 <212> PRT <213> Artificial Sequence <400> 159 Ile Thr Ser Gly Gly Lys Ala 1 5 <210> 160 <211> 15 <212> PRT <213> Artificial Sequence <400> 160 His Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala 1 5 10 15 <210> 161 <211> 7 <212> PRT <213> Artificial Sequence <400> 161 Gly Gly Thr Phe Val Ile Asn 1 5 <210> 162 <211> 7 <212> PRT <213> Artificial Sequence <400> 162 Ile Ser Tyr Gly Gly Ser Thr 1 5 <210> 163 <211> 15 <212> PRT <213> Artificial Sequence <400> 163 Arg Leu Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr 1 5 10 15 <210> 164 <211> 8 <212> PRT <213> Artificial Sequence <400> 164 Gly Phe Thr Phe Ser Asn Tyr Ala 1 5 <210> 165 <211> 8 <212> PRT <213> Artificial Sequence <400> 165 Ile Asn Ser Gly Gly Asp Asn Thr 1 5 <210> 166 <211> 11 <212> PRT <213> Artificial Sequence <400> 166 Ala Arg Glu Glu Glu Asn Ala Gly Thr Ile Leu 1 5 10 <210> 167 <211> 8 <212> PRT <213> Artificial Sequence <400> 167 Gly Ser Ile Ala Asn Ile Gln Val 1 5 <210> 168 <211> 9 <212> PRT <213> Artificial Sequence <400> 168 Ile Thr Val Thr Gly Asp Arg Ala Thr 1 5 <210> 169 <211> 11 <212> PRT <213> Artificial Sequence <400> 169 Asn Ala Arg Ser Tyr Tyr Gly Gln His Asn Tyr 1 5 10 <210> 170 <211> 8 <212> PRT <213> Artificial Sequence <400> 170 Gly Val Thr Phe Ser Ile Asn Ala 1 5 <210> 171 <211> 7 <212> PRT <213> Artificial Sequence <400> 171 Ile Ser Ser Gly Gly Ser Thr 1 5 <210> 172 <211> 15 <212> PRT <213> Artificial Sequence <400> 172 Asn Ala Asp Val Val Gly Ser Ser Trp Ser Pro Glu Tyr Asp Tyr 1 5 10 15 <210> 173 <211> 8 <212> PRT <213> Artificial Sequence <400> 173 Gly Ser Ile Phe Thr Ile Asn Ile 1 5 <210> 174 <211> 7 <212> PRT <213> Artificial Sequence <400> 174 Ile Asn Arg Val Gly Asp Thr 1 5 <210> 175 <211> 15 <212> PRT <213> Artificial Sequence <400> 175 Asn Ala Asp Ile Val Glu Ser Gly Arg Tyr Ser Gly Lys Asp Tyr 1 5 10 15 <210> 176 <211> 8 <212> PRT <213> Artificial Sequence <400> 176 Gly Ile Ile Leu Asp Tyr Tyr Pro 1 5 <210> 177 <211> 11 <212> PRT <213> Artificial Sequence <400> 177 Ile Thr Ser Ser Asp Asp Ser Thr Val Tyr Thr 1 5 10 <210> 178 <211> twenty two <212> PRT <213> Artificial Sequence <400> 178 Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Tyr His Thr Leu Asn 1 5 10 15 Ser Ser Asp Phe Asp Tyr 20 <210> 179 <211> 8 <212> PRT <213> Artificial Sequence <400> 179 Gly Asn Ser Leu Gly Val Tyr Asn 1 5 <210> 180 <211> 7 <212> PRT <213> Artificial Sequence <400> 180 Ile Asn Ser Arg Gly Asp Thr 1 5 <210> 181 <211> 12 <212> PRT <213> Artificial Sequence <400> 181 Ile Ala Gln Arg Gly Trp Gly Arg Glu Tyr Asp Ile 1 5 10 <210> 182 <211> 8 <212> PRT <213> Artificial Sequence <400> 182 Gly Ser Thr Leu Ser Leu His Ser 1 5 <210> 183 <211> 7 <212> PRT <213> Artificial Sequence <400> 183 Ile Ser Arg Asp Gly Asp Ser 1 5 <210> 184 <211> 11 <212> PRT <213> Artificial Sequence <400> 184 Asn Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu 1 5 10 <210> 185 <211> 5 <212> PRT <213> Artificial Sequence <400> 185 Gly Ser Ile Phe Ser 1 5 <210> 186 <211> 8 <212> PRT <213> Artificial Sequence <400> 186 Ile Ala Asn Gly Gly Thr Thr Thr 1 5 <210> 187 <211> 11 <212> PRT <213> Artificial Sequence <400> 187 Tyr Ala Lys Arg Ser Trp Asp Ser Ser Ser Tyr 1 5 10 <210> 188 <211> 8 <212> PRT <213> Artificial Sequence <400> 188 Gly Phe Thr Leu Asp Tyr Tyr Ala 1 5 <210> 189 <211> 8 <212> PRT <213> Artificial Sequence <400> 189 Ile Asn Ser Gly Asp Ser Ser Thr 1 5 <210> 190 <211> twenty one <212> PRT <213> Artificial Sequence <400> 190 Ala Thr Val Asp Thr Leu Ile Val Ala Gly Asn Leu Glu Glu Cys Arg 1 5 10 15 Tyr Asp Met Asp Tyr 20 <210> 191 <211> 217 <212> PRT <213> Artificial Sequence <400> 191 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 115 120 125 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155 160 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 192 <211> 15 <212> PRT <213> Artificial Sequence <400> 192 Glu Pro Lys Ser Ala Asp Lys Thr His Thr Cys Pro Pro Cys Pro 1 5 10 15 <210> 193 <211> 125 <212> PRT <213> Artificial Sequence <400> 193 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Tyr Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 194 <211> 125 <212> PRT <213> Artificial Sequence <400> 194 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 195 <211> 125 <212> PRT <213> Artificial Sequence <400> 195 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 196 <211> 125 <212> PRT <213> Artificial Sequence <400> 196 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 197 <211> 125 <212> PRT <213> Artificial Sequence <400> 197 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Gln 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 198 <211> 125 <212> PRT <213> Artificial Sequence <400> 198 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Gly 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 199 <211> 125 <212> PRT <213> Artificial Sequence <400> 199 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 200 <211> 125 <212> PRT <213> Artificial Sequence <400> 200 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asn 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 201 <211> 125 <212> PRT <213> Artificial Sequence <400> 201 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Thr Ser Asp 20 25 30 Asp Met Asp Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln 35 40 45 Arg Glu Trp Val Ala Thr Ile Thr Ser Asp Glu Asp Thr Asn Tyr Val 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 65 70 75 80 Ser Ala Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Phe Ala Asn Val Arg Ser Asp Arg Ser Ser Leu Tyr Arg 100 105 110 Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 202 <211> 130 <212> PRT <213> Artificial Sequence <400> 202 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Asn Ser Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 203 <211> 130 <212> PRT <213> Artificial Sequence <400> 203 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Ser Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Asn Ser Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 204 <211> 130 <212> PRT <213> Artificial Sequence <400> 204 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Pro Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Asn Ser Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 205 <211> 130 <212> PRT <213> Artificial Sequence <400> 205 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Pro Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Ser Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Asn Ser Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 206 <211> 130 <212> PRT <213> Artificial Sequence <400> 206 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Lys Asn Thr Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 207 <211> 130 <212> PRT <213> Artificial Sequence <400> 207 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Ser Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Lys Asn Thr Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 208 <211> 130 <212> PRT <213> Artificial Sequence <400> 208 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Leu Asp Tyr Tyr 20 25 30 Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Arg Glu Gly Val 35 40 45 Ala Phe Ile Thr Asn Ser Asp Asp Ser Thr Ile Tyr Thr Asn Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Asn Ser Leu 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Ala Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu 100 105 110 Asn Ser Ala Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Met Val Thr Val 115 120 125 Ser Ser 130 <210> 209 <211> 121 <212> PRT <213> Artificial Sequence <400> 209 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 210 <211> 121 <212> PRT <213> Artificial Sequence <400> 210 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys Asn Ser Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 211 <211> 121 <212> PRT <213> Artificial Sequence <400> 211 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 212 <211> 121 <212> PRT <213> Artificial Sequence <400> 212 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asn Asp Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 213 <211> 121 <212> PRT <213> Artificial Sequence <400> 213 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Ser Thr Ser Ser Leu Ser 20 25 30 Leu Met Ser Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Ser Ile Thr Ser Gly Gly Lys Ala Asn Tyr Val Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95 Ala Tyr Asp Arg Ala Gly Thr Ala Ser Gly Phe Gly Ala Ala Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 214 <211> 120 <212> PRT <213> Artificial Sequence <400> 214 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Asn 20 25 30 Ala Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 35 40 45 Ser Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 50 55 60 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 65 70 75 80 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg Leu 85 90 95 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 215 <211> 120 <212> PRT <213> Artificial Sequence <400> 215 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Val Ile Asn 20 25 30 Ala Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 35 40 45 Ser Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 50 55 60 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 65 70 75 80 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg Leu 85 90 95 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 216 <211> 120 <212> PRT <213> Artificial Sequence <400> 216 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Val Ile Asn 20 25 30 Ala Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 35 40 45 Ser Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 50 55 60 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 65 70 75 80 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg Leu 85 90 95 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 217 <211> 120 <212> PRT <213> Artificial Sequence <400> 217 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Val Ile Asn 20 25 30 Ala Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 35 40 45 Ser Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 50 55 60 Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Val Tyr Leu Gln 65 70 75 80 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg Leu 85 90 95 Asp Pro Gly Leu Ala Leu Asn Asn Arg Pro Leu Tyr Tyr Trp Gly Gln 100 105 110 Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 218 <211> 117 <212> PRT <213> Artificial Sequence <400> 218 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 219 <211> 117 <212> PRT <213> Artificial Sequence <400> 219 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 220 <211> 117 <212> PRT <213> Artificial Sequence <400> 220 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Leu Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 221 <211> 117 <212> PRT <213> Artificial Sequence <400> 221 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Leu Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Gly Thr Lys Asn Ser Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 222 <211> 117 <212> PRT <213> Artificial Sequence <400> 222 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Leu Ser Leu His 20 25 30 Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Ser Arg Asp Gly Asp Ser Asn Tyr Leu Ser Ser Leu Ala 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Gly Thr Lys Asn Ser Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Arg Thr Ser Pro Trp Ser Ala Ala Leu Trp Gly Gln Gly Thr Met 100 105 110 Val Thr Val Ser Ser 115 <210> 223 <211> 118 <212> PRT <213> Artificial Sequence <400> 223 Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Asn Ser Gly Gly Asp Asn Thr Tyr Tyr Ala Tyr Phe Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Glu Glu Glu Asn Ala Gly Thr Ile Leu Gln Gly Gln Gly Thr 100 105 110 Gln Val Thr Val Ser Ser 115 <210> 224 <211> 98 <212> PRT <213> Artificial Sequence <400> 224 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 225 <211> 11 <212> PRT <213> Artificial Sequence <400> 225 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 1 5 10 <210> 226 <211> 12 <212> PRT <213> Artificial Sequence <400> 226 Gly Ser Ile Phe Thr Ser Gln Asp Met Asp Tyr Ala 1 5 10 <210> 227 <211> 12 <212> PRT <213> Artificial Sequence <400> 227 Gly Ser Ile Phe Thr Ser Asn Asp Met Asp Tyr Ala 1 5 10 <210> 228 <211> 20 <212> PRT <213> Artificial Sequence <400> 228 Arg Ser Thr Tyr Ile Val Gly Arg Asn Glu Asn Ala Leu Asn Ser Ala 1 5 10 15 Asp Tyr Asp Tyr 20 <210> 229 <211> 20 <212> PRT <213> Artificial Sequence <400> 229 Phe Ile Thr Asn Ser Asp Ser Ser Thr Ile Tyr Thr Asn Tyr Ala Asp 1 5 10 15 Ser Val Lys Gly 20 <210> 230 <211> 16 <212> PRT <213> Artificial Sequence <400> 230 Ser Ile Ser Tyr Gly Gly Ser Thr Asn Tyr Ala Asp Arg Val Ala Gly 1 5 10 15

Claims

1. An antibody or antigen-binding fragment that specifically binds to CD33, characterized in that, The antibody or antigen-binding fragment includes: CDR1, CDR2, and CDR3; (1) According to the KABAT encoding, the amino acid sequences of CDR1, CDR2 and CDR3 are as shown in SEQ ID NO: 53, SEQ ID NO: 54, 230 and SEQ ID NO: 55, respectively; (2) According to the Chothia coding, the amino acid sequences of CDR1, CDR2 and CDR3 are as shown in SEQ ID NO: 107, SEQ ID NO: 108 and SEQ ID NO: 109, respectively; (3) According to the IMGT encoding, the amino acid sequences of CDR1, CDR2 and CDR3 are as shown in SEQ ID NO: 161, SEQ ID NO: 162 and SEQ ID NO: 163, respectively; The antibody is a heavy chain antibody, a single-domain antibody, or a nanobody, and the antigen-binding fragment is a VHH domain.

2. The antibody or antigen-binding fragment according to claim 1, characterized in that, The amino acid sequence of the VHH domain is shown in SEQ ID NO:19 or SEQ ID NO:

217.

3. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, Its dissociation constant when it binds to human CD33 is no greater than 100 nM; its dissociation constant when it binds to monkey CD33 is no greater than 100 nM.

4. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, The antibody or antigen-binding fragment may or may not contain an antibody heavy chain constant region; the antibody heavy chain constant region may be selected from human, alpaca, mouse, rat, rabbit, or sheep.

5. The antibody or antigen-binding fragment according to claim 4, characterized in that, The constant region of the antibody heavy chain is selected from IgG, IgM, IgA, IgE or IgD, and the IgG is selected from IgG1, IgG2, IgG3 or IgG4.

6. The antibody or antigen-binding fragment according to claim 5, characterized in that, The heavy chain constant region is selected from the Fc region, the CH3 region, the heavy chain constant region without CH1 fragments, or the complete heavy chain constant region.

7. The antibody or antigen-binding fragment according to claim 6, characterized in that, The heavy chain constant region has an amino acid sequence as shown in SEQ ID NO:

191.

8. The antibody or antigen-binding fragment according to claim 5, characterized in that, The antibody or antigen-binding fragment is a heavy chain antibody.

9. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, The antibody or antigen-binding fragment is: (1) Chimeric antibody or fragment thereof; or, (2) Humanized antibodies or fragments thereof.

10. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, The antibody or antigen-binding fragment is also coupled with a tracer.

11. The antibody or antigen-binding fragment according to claim 10, characterized in that, The tracer is selected from radiographic contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents, and photosensitizers.

12. The antibody or antigen-binding fragment according to claim 1 or 2, characterized in that, The antibody or antigen-binding fragment is also linked to another functional molecule, which is selected from: signal peptides and protein tags.

13. A chimeric antigen receptor, characterized in that, The chimeric antigen receptor comprises at least an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen-binding domain comprises the antibody or antigen-binding fragment as described in any one of claims 1 to 9.

14. An immune effector cell, characterized in that, The immune effector cells express the chimeric antigen receptor of claim 13, or contain a nucleic acid fragment encoding the chimeric antigen receptor of claim 13.

15. The immune effector cell according to claim 14, characterized in that, The immune effector cells are selected from T cells, NK cells, NKT cells, DNT cells, monocytes, macrophages, dendritic cells, or mast cells.

16. The immune effector cell according to claim 15, characterized in that, The T cells are selected from cytotoxic T cells, regulatory T cells, or helper T cells.

17. The immune effector cell according to claim 14, characterized in that, The immune effector cells are autologous immune effector cells or allogeneic immune effector cells.

18. An isolated nucleic acid fragment, characterized in that, The nucleic acid fragment encodes the antibody or antigen-binding fragment as described in any one of claims 1 to 9, or the chimeric antigen receptor as described in claim 13.

19. A vector, characterized in that, The vector comprises the nucleic acid fragment of claim 18.

20. A host cell, characterized in that, The host cell comprises the vector of claim 19.

21. The host cell according to claim 20, characterized in that, The cells are either prokaryotic or eukaryotic cells.

22. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises an antibody or antigen-binding fragment as described in any one of claims 1 to 9, or an immune effector cell as described in any one of claims 14 to 17, or a nucleic acid fragment as described in claim 18, or a carrier as described in claim 19.

23. The pharmaceutical composition according to claim 22, characterized in that, The pharmaceutical composition may also contain a pharmaceutically acceptable carrier, diluent, or adjuvant.

24. Use of the antibody or antigen-binding fragment of any one of claims 1 to 9, or the immune effector cell of any one of claims 14 to 17, or the nucleic acid fragment of claim 18, or the carrier of claim 19, or the pharmaceutical composition of any one of claims 22 or 23 in the preparation of a medicament for the prevention and / or treatment of tumors, wherein the tumor is selected from myelodysplastic syndromes, acute myeloid leukemia, chronic myeloid leukemia, and promyelocytic leukemia.

Citation Information

Patent Citations

  • RNA-coded antibody

    EP2101823B1

  • Anti-CD33 antibodies, Anti-CD33 / Anti-CD3 bispecific antibodies and uses thereof

    US20190382481A1

  • Method for making heteromultimeric polypeptides

    US5821333A

  • Activated carbon filtration for purification of benzodiazepine ADCs

    US9453046B2

  • Immunoglobulins devoid of light chains

    WO1994004678A1